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ABSTRACT 
 
 Congenital heart defects are the number one cause of birth defect-related 
deaths. Cardiovascular diseases are the most common cause of death worldwide. 
Layered cellular sheet constructs offer one very valuable option for cardiac patch 
implantation during surgical treatment of both pediatric and adult patients with 
cardiac defects or damage. A very exciting, relatively unexplored, autologous, 
available cell source for making patches are placenta-derived mesenchymal stem 
cells (pMSCs). In this study, pMSCs were assessed as a potential cell source for 
cardiac repair and regeneration by evaluating their differentiation capacity into 
cardiomyocytes, their effects on cardiac cell migration and proliferation, and their 
ability to be grown into cell sheets. It was found that pMSC cardiac protein content 
was enhanced by differentiation media treatment, but no beating cells were 
produced. Undifferentiated pMSCs improved migration and proliferation of a 
cardiac cell population and formed intact, aligned cell sheets. However, like many 
new cell sources for cardiac repair, pMSCs should still be functionally 
  vii 
characterized to understand how compatible they will be with resident heart tissue. 
Implanting non-autologous, potentially pluripotent, non-myocyte (non-beating) 
cells presents concerns regarding electromechanical mismatch and implant 
rejection. The characterization of non-traditional cell sources such as pMSCs 
motivated the design of a bio-MEMS device that assesses contractile force and 
conduction velocity in response to electrical and mechanical stimulation of a cell 
source as it is grown and once it forms a cellular sheet. This ideally creates the 
ability for patient specific cell sheets to be cultured, characterized, and conditioned 
to be compatible with the patient’s cardiac environment in vitro, prior to 
implantation. In this work, the device was designed to achieve the following: 
cellular alignment, electrical stimulation, mechanical stimulation, conduction 
velocity readout, contraction force readout, and upon characterization, cell sheet 
release. The platform is based on a set of comb electrical contacts which are three-
dimensional wall contacts made of polydimethylsiloxane and coated with 
electrically conductive metals. Device fabrication and initial validation experiments 
were completed as part of this study; ultimately the device will allow for the 
complete functional characterization and conditioning of variable cell source cell 
sheet implants for myocardial implantation.  
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CHAPTER ONE: INTRODUCTION 
 
1.1 General Description of the Problem  
Congenital heart defects (CHDs) 
are the number one birth defect 
(incidence: ~40,000/year in the U.S.)2,7,8 
and the leading cause of birth defect-
related illness and death. CHDs are 
defects present at birth that affect the 
strength and or structure of the interior 
walls, valves, and or arteries/veins 
present in or attached to the heart. For 
example, the most common CHD, a 
ventricular septal defect, is an opening 
between the ventricles which allows 
shunting of blood from the left to the right 
chamber. It can be surgically treated by 
implanting a patch or baffle across the defect. Tetralogy of Fallot, another common 
CHD, prevents blood from being sent to the lungs; it also requires the placement 
of patches in ventricular wall regions during surgical repair9.
1.11 Current Solutions 
Currently the most widely used surgical patch solutions include the use of 
synthetic materials such as Dacron, Gore-Tex, and ePTFE as well as the use of 
Fig 1 Common congenital heart defects that 
can be surgically fixed with the use of cardiac 
patch implants. Figure from American Heart 
Association2. 
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biological materials such as autologous, allogenic, and xenogenic pericardium.  
These materials are effective in that they are available, cause limited immune 
response, and have been successfully adopted into surgical practice. Current 
interventions that utilize these patches to ameliorate congenital heart defects allow 
survival into adulthood; however, xenograft/allograft rejection, inflammation, 
thrombus and inability of the patch to grow as the patient matures limit the effective 
lifetime of implanted materials and lead to frequent reoperation.  
An ideal patch material is non-thrombogenic, resists infections, lacks 
antigenicity, grows with the tissue, has long durability, and either directly 
strengthens the surrounding tissue via rapid incorporation and growth with the 
organism or releases paracrine signals that recruit cardiac resident and progenitor 
cells to locations in need of repair and remodeling. One method for tissue 
engineering this type of patch is by fabricating it from cells and extracellular matrix 
material only; this can be achieved by stacking monolayer cellular sheets on top 
of each other. Individual cell sheets can be fabricated from any number of cell 
sources by seeding them onto a substrate that allows for proliferation, extracellular 
matrix deposition, and triggered release of the cell sheet from the substrate, 
providing a scaffold-less implant. Released sheets can be stacked to enhance 
mechanical properties and overall patch durability. In theory, different sheets can 
be made from different cell types and sheets can be patterned and conditioned for 
different applications.  
A major issue for autologous implants – in this case, stacked cell sheets – 
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is cell source availability, especially for pediatric patients where the absolute 
number of cardiomyocytes that can be isolated from discarded heart tissue is 
insufficient to enable construction of effectively sized sheets. Thus researchers 
have turned to other options including progenitor, pluripotent, embryonic, and 
mesenchymal stem cells (MSCs)10-17. MSCs have been a focus of both research 
and therapeutic study since their first isolation and characterization in 1974 and 
their use in the first human clinical trial in 200418. Of the 344 clinical trials ongoing 
in 2013, 22.9% were related to treating myocardial infarction with many past and 
present studies reporting improved heart function18-20.  
1.12 pMSCs as Source for Engineered Tissue Patches  
Placental mesenchymal stem cells (pMSCs) are a very exciting, relatively 
unexplored and non-
controversial cell source that 
can be collected and cultured 
in advance of their surgical 
need21-25. The placenta, 
normally discarded at birth, 
provides immediate access 
to a large number of cells 
(not otherwise available in a 
newborn patient). In addition 
to immunosuppressive 
Fig 2 Design motivation and clinical application of a bio-
MEMS device that allows for stimulation and functional 
characterization of cell sheet implants. 
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effects that allow MSCs in general to avoid allogeneic barriers to implantation, 
pMSCs are expected to further reduce immune response as they are cultured from 
tissue from the fetal side of the mother’s placenta, making them more genetically 
similar than cells from an unrelated donor.  
However, as pMSCs are not the patient’s resident cardiomyocytes, it is 
necessary to evaluate how they will function in a cardiac environment. How do we 
effectively evaluate how these cells will behave in vivo once implanted – especially 
when normal cardiac function is already affected by a defect? How do we optimize 
a patch prior to implantation such that it has the best chance not only for 
incorporation but actually repairing the myocardium? It is one thing to implant 
autologous cardiomyocytes in the patient as there is a relatively low risk for 
immune response, mismatched electromechanics, and or increased scarring at the 
implant site. However, implanting non-autologous, potentially pluripotent, non-
myocyte (non-beating) cells in these same locations presents a host of concerns, 
creating a need for a standardized method for cell culture, functional evaluation, 
and conditioning of variable cell sources prior to implantation.  
Premise: developing a device and protocol for functional evaluation 
will determine if pMSCs are a viable cell source for engineering myocardial 
patches. 
1.13 Additional Applications  
While the initial motivation and the focus of this work is to engineer and 
evaluate pMSC cell sheets, the device and methods described herein are not 
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limited to surgical patches for CHDs. Cardiovascular diseases (CVD) are the most 
common cause of death worldwide with an estimated 17.7 million people dying 
from them in 2015, 31% of all global deaths26. Ischemic heart disease and stroke 
are the primary diseases responsible for these deaths and have been so for the 
past 15 years26. Engineered tissue replacements for this type of damaged 
myocardium are needed as well. The designed device could ultimately result in the 
production of safer, patient specific, more cardiac compatible tissue engineered 
solutions for both CHD and CVD problems.  
1.2 Significance of Research Presented 
Though today there is extensive completed and ongoing research focused 
on cell sources and solutions for damaged myocardium, there are multiple 
remaining design challenges associated with creating safe, functioning cardiac 
implants that need to be bridged before realizing clinical application27. Native 
myocardium is formed from a high density of aligned myocytes and supporting 
cells that contract synchronously according to electrical signal propagation 
throughout the tissue28. These structural and functional needs require finding an 
abundant and compatible cell population that will ensure reliable 
electromechanical function once implanted.  
There is a need for a standardized method to evaluate myocardial 
patches intended for patient implantation that have been made from new, 
variable cell sources. A single device enabling parallel culture and functional 
evaluation of cell sheets in a cardiac environment prior to implantation could 
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ultimately result in production of safe, patient-specific, cardiac-compatible tissue-
engineered solutions to current cardiac problems. The proposed bio-MEMS device 
provides a platform to evaluate contractile force and conduction velocity of cell 
sheets in response to electromechanical stimulation as they grow. This provides a 
standard method to functionally evaluate new potential cell sources including, but 
not limited to, pMSCs for myocardial repair. Major innovative elements of this 
device include: real-time data for rich understanding of engineered tissues as they 
are grown, ability to expose engineered tissues to specific patient-derived stimuli, 
and the option to implant after characterization. These are significant 
developments to bring tissue engineering one step closer to clinical realization. It 
is important to establish methods and standards that can be agreed upon and used 
by researchers and clinicians throughout the field to determine which tissue 
engineered constructs are in fact safe and beneficial for implantation.  
In order to expand on the motivation and outline the structure of this 
work, general information related to cardiac tissue engineering will be 
reviewed in the introduction before delving deeper into a literature review of 
specific technology relevant to the experimental work presented. 
1.3 Cardiac Tissue Engineering 
1.31 Tissue Engineering, Regenerative Medicine, and Cell Sheets 
During the 1980s, in response to the lack of sufficient organs for 
transplantation, tissue engineering was first proposed by chemist Dr. R. Langer 
and surgeon Dr. J.P. Vacanti as the following idea: seeding biodegradable material 
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scaffolds with living cells, culturing them outside the body, and then implanting 
these seeded constructs into a patient in need of an organ or tissue replacement29. 
Scientists hypothesized that the cells would eventually degrade the material upon 
implantation and the constructs would become vascularized and well incorporated 
within native tissue. The challenges associated with realizing this technology at 
that time persist now: cell sourcing and functional performance, organizing cells 
into a 3D architecture that mimics tissue, and the construct’s remodeling of or 
incorporation within the living system. Advances have been made in tissue 
engineering as it relates to skin, cartilage, blood vessel, and other organ repair and 
reconstruction, but actual therapeutic use is fairly limited.  
Dr. Teruo Okano’s group sought to overcome many of the barriers to clinical 
use by using cell sheet technology for tissue engineered patches, as it 
recapitulates the natural structure of organs: interconnected layers of different cell 
types are stacked to form a continuous 3D tissue. Temperature responsive culture 
dishes are used to grow and subsequently release cell sheets. In brief, poly(N-
isopropylacrylamide), is a temperature-responsive polymer used to coat the 
culture surface; at 37°C, the surface is relatively hydrophobic allowing cells to 
attach and grow, while below 32°C the surface becomes hydrophilic which 
promotes a spontaneous lift up of the cells30.  After establishing the technology in 
199830, today Dr. Okano has helped to initiate a clinically available cardiac patch 
on the market in Japan, HeartSheet, by Terumo Corporation. Currently the product 
is used for the treatment of severe heart failure caused by chronic ischemic heart 
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disease. The patches are skeletal myoblast sheets cultured from the patient’s own 
skeletal muscle tissue which are then implanted into the patient’s heart.  
Over the past two decades, the number of full heart transplants performed 
has remained constant at 2,000-2,50031 and yet the number of people in need of 
a new heart continues to rise. The need for implant substitutes is evident.  Tissue 
engineering is still a developing clinical technology, but cellular sheets for 
cardiac implantation are beginning to see human clinical trials, suggesting 
potential for tissue engineered constructs in the near future.  
1.32 Heart Function and Clinical Assessment 
Recapitulating tissue for any organ is very challenging; the heart is no 
exception. Tissues such as myocardium, the muscle wall which makes up the 
majority of the heart, represent specialized collections of cells and cell products 
that are systematically arranged to work together to carry out specific biological 
functions. While tissues are regulated at the cellular level by biochemical and 
mechanical cues present within their surrounding microenvironment, ultimately it 
is the hierarchical organization of the tissue structure that dictates its overall 
function. If the loss of tissue structure/function is too extensive or repair is 
ineffective, the organism’s ability to recover or even survive is jeopardized. The 
heart, as evident by the consistently high number of deaths due to cardiovascular 
disease, is one organ where loss of tissue structure and function is detrimental to 
the organism’s survival. In order to understand the extreme complexity of these 
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relationships, a brief overview of the heart from the macroscopic to the molecular 
level is covered. 
The heart is a double-sided pump which drives oxygenated blood 
throughout the body and de-oxygenated blood through the lungs where it is re-
oxygenated. When the heart beats, a cellular process allows for the synchronous 
contractility associated with this organ’s ability to pump. Contraction of cardiac 
muscle occurs because of the sliding of myosin filaments along actin filaments to 
shorten and lengthen the muscle fiber during contraction and relaxation. In order 
for this to occur, pacemaker cells located in the sinoatrial node exhibit regular, 
spontaneous action potentials caused by the flux of Ca2+, K+, and Na+ ions. These 
action potentials are conducted from the pacemaker cells to contractile 
cardiomyocyte cells through gap junctions (often formed by proteins called 
connexins) where they travel between sarcomeres, activate the calcium channels 
in the T-tubules of the cells, and allow the influx of calcium ions into the cell. 
Calcium in the cytoplasm binds to cardiac troponin, which moves it away from the 
actin binding site, freeing the actin to bind to the myosin and initiate contraction as 
the myosin head can pull the actin filament toward the center of the sarcomere. As 
intracellular calcium is removed by the sarcoplasmic reticulum, the reduced 
calcium concentration allows the cardiac troponin complex to return to its inhibiting 
position on the active site of actin and contraction ends32,33.  
This coordinated pacemaker stimulation and subsequent myocyte 
contraction, allows for the macroscopic pumping of de-oxygenated blood into the 
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right atrium from the body, to the right ventricle, to the lungs for oxygen, back to 
the left atrium, to the left ventricle, and out to the rest of the body. This electrical 
and mechanical motion can be clinically recorded through electrocardiography 
(EKG) and echocardiography (ECHO) respectively. EKG is a recording of the 
heart’s electrical activity that is collected using electrodes placed on the skin; these 
electrodes can detect the electrical changes arising from the muscle depolarizing 
and repolarizing during each heartbeat. In brief, the heart’s electrical potential is 
measured from 12 different angles such that the overall magnitude and direction 
of the heart’s electrical depolarization is captured throughout the beat cycle. The 
plot of this voltage over time is the EKG; in a healthy heart, there is an expected 
progression of depolarization starting with the pacemaker cells in the sinoatrial 
node, spreading through the atrium, then atrioventricular node down the bundle of 
His and into the Purkinje fibers, and finally throughout the ventricles. This signature 
trace as well as deviations from it give trained clinicians information about the 
structure of the heart and the function of its electrical conduction system. Echo 
uses 2D, 3D, and Doppler ultrasound to create images of the heart. It can be used 
to determine chamber size and shape, cardiac output, ejection fraction, diastolic 
function, and if any tissue damage is present. The Doppler ultrasound can be used 
to visualize blood flow through the heart.  
The heart demands complex synchronization of electrical and 
mechanical function. A myocardial implant must be compatible with the 
electro-mechanics in place. There are established clinical tools for 
  
11 
evaluating and assessing proper function that can guide researchers in 
evaluating their constructs for implantation. 
1.33 Cell Sources for Myocardial Regeneration  
The leading cell sources for myocardial applications are cardiac progenitor 
cells (CPCs), inducible pluripotent stem cells (iPS), and mesenchymal stem cells 
(MSCs). Until recently the heart was considered post-mitotic, but cardiomyocyte 
renewal in postnatal mammals is actually on the order of 1% per year34. Cardiac 
progenitor cells are a heterogeneous group of cells distributed throughout the heart 
that are activated by myocardial injury and may differentiate into new myocytes or 
vascular cells35. Several markers and methods have been documented in the 
literature for isolating different populations of progenitor cells based on surface 
markers or cell characteristics: c-kit+, Sca-1+, Isl-1+, cardiosphere-derived, and 
cardiac side population cells among others documented in the literature. These 
cells are promising because they are endogenous to the heart and showed 
preliminary positive clinical results when injected during the CADUCEUS and 
SCIPIO clinical trials36,37. However, the cell type is loosely defined, inconsistently 
isolated, and the mechanism for improved cardiac function is still not entirely 
understood. iPS cells are a type of pluripotent cell that can be generated by 
reprogramming adult somatic cells through exposure to four specific genes 
encoding transcription factors: Oct4, Sox2, cMyc, and Klf4. iPS cells can propagate 
indefinitely and have been successfully differentiated into other cell types, 
including beating cardiomyocytes. They can be derived from the patient’s own 
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cells, providing an abundant, autologous cell source, but therapeutic transplants 
have not been deemed safe due to concerns about teratoma formation. Finally, 
MSCs can be isolated from numerous tissues including bone marrow, cord blood, 
adipose tissue, amniotic fluid, and placenta among others. They maintain 
multipotency while being expanded in culture and as stated previously have been 
used in numerous clinical trials. MSCs from various tissues have been 
differentiated into cells sharing characteristics of cardiomyocytes38-40. MSCs have 
been injected into the heart during clinical trials and improved heart function18-20. 
There is still a debate over how MSCs provide cardiac benefit, whether it is through 
the process of MSC differentiation into a cardiomyocyte phenotype or it is the 
undifferentiated MSC positive paracrine effects41-43 on resident cardiac cells.  
Multiple protocols exist for (1) the generation of cardiomyocytes via 
differentiation of various adult progenitor, inducible pluripotent, and 
mesenchymal stem cell sources and (2) the implantation of these cells in 
their undifferentiated or differentiated forms10-16. The selection of the right 
cell source for cardiac repair is ongoing with each cell type presenting 
various pros and cons, suggesting multiple options may eventually be 
employed in cardiac therapy in the clinical setting and making it even more 
critical to establish a standard system for implant evaluation. 
1.4 Scope and Specific Aims 
The field of cardiac tissue engineering is vast. The discussion herein will be 
limited to mesenchymal stem cells, cell sheet engineering, electrical and 
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mechanical cellular measurements, and electrical and mechanical stimulation 
techniques as they apply to cardiac tissue engineering. The documented work has 
been completed in pursuit of the following three aims, which will be expanded upon 
in the core of this document, Chapters III-V: 
Specific Aim 1: Identify a cell source (mesenchymal stem cells) that can 
be isolated from placental chorion and amnion tissue (pMSCs). 
Characterize potential for myocardial therapy. 
Specific Aim 2: Build Bio-MEMs device for functional (conductive, 
mechanical) characterization and conditioning of cells for myocardial 
patches. 
Specific Aim 3: Validate use of device with variable cell sources.
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CHAPTER TWO: LITERATURE REVIEW 
 
The literature review can be divided into two sections: (1) mesenchymal 
stem cells, as related to work in aim 1 and (2) electrical/mechanical measurement 
and stimulation of cell sources for cardiac applications as related to work in aims 
2 and 3. 
2.1 Mesenchymal Stem Cells for Clinical Cardiac Therapy 
2.11 MSC Potential for Cardiac Therapy 
MSCs have been isolated from many cell sources: bone marrow, adipose 
tissue, umbilical cord blood, dental pulp, synovial fluid, amniotic fluid, urine, 
Wharton’s jelly, and placenta. MSCs from different sources share many 
characteristics, but also can vary depending on the niche from which they 
originate, the culture conditions, and isolation procedures. MSCs have been shown 
Fig 3 Table of cardiac clinical trials with MSCs. Figure from Majka et al1 . 
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to differentiate into cardiomyocytes (among other cells types). However, more 
recent research suggests that this may not be their primary mechanism of action 
in cardiovascular regeneration1. Paracrine secretion and cell-cell interactions by 
MSCs at the site of implantation affect tissue repair and regeneration. MSCs 
secrete cytokines that induce cardioprotection and stimulate angiogenesis; they 
also secrete metalloproteinases that are able to reorganize the ECM in scar tissue. 
MSCs stimulate the proliferation and differentiation of endogenous cardiac stem 
cells, recruiting other stem cells to facilitate regeneration of the injured tissue. In 
addition, MSCs have immunoprivilege, meaning they do not trigger an 
immunologic reaction when non-autologous cells are used and have an anti-
inflammatory effect on the site of implantation.1  
2.12 Clinical Trial Results to Date1 
Listed in Figure 3 are examples of clinical trials to date. Most clinical trials 
are targeted at treating myocardial infarction or chronic ischemic cardiomyopathy. 
MSCs from bone marrow, adipose tissue, or Wharton’s Jelly have been used for 
injection into the heart. Common observations include no rejection or other 
adverse effect on cells, small improvements to ejection fraction and heart 
contractility, and reduced scarring. Unfortunately, to date, effects observed in 
preclinical studies are still stronger than those seen in clinical trials. MSC source, 
method of isolation, and method of delivery must be further optimized to improve 
clinical outcome. Two methods presented here for improving clinical 
outcomes are (1) increasing MSC retention by implanting as a cellular sheet 
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and not cellular injection and (2) pre-conditioning MSCs with cardiac 
stimulation conditions may be one way to improve clinical outcome. 
2.2 Electrical and Mechanical Measurement and Stimulation 
2.21 Motivation for Electrical Measurements 
The beating of heart muscle is initiated by pacemaker cells capable of 
spontaneous depolarization in a rhythmic fashion (automaticity), which generates 
action potentials when a specific threshold voltage is reached. These pacemaker 
cells, found in the sinoatrial node, then depolarize neighboring cardiomyocytes, as 
positive ions in the pacemaker cells flow through gap junctions to the adjacent 
contractile cells, in turn triggering their action potentials. In this way, gap junctions 
allow for all cardiomyocytes in the heart to contract in a coordinated fashion as the 
wave of depolarization moves through the tissue. Action potentials are functions 
of the transmembrane potential (TMP), the electrical potential between the inside 
and outside of the cell; as positive ions move into the cell, the TMP becomes more 
positive. Ion channels within the cell membrane maintain the ionic gradients and 
charge differentials in cardiomyocytes; the channels are selectively permeable to 
single types of ions and only open during specific TMP ranges. At the beginning of 
Fig 4 Equivalent circuit diagram for cell membrane potential. 
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the action potential cycle for non-pacemaker cardiomyocytes, the resting TMP of 
cardiomyocytes is -90 mV as maintained by an outward leak of K+ ions and closed 
Na+ and Ca2+ channels. During depolarization, positive ions from a neighboring 
cell cause the TMP to rise above -90 mV, triggering Na+ channels to open very 
rapidly and causing the TMP to quickly overshoot 0 mV, before returning to 0 mV 
as K+ continues to leak out and Ca2+ begins to flow slowly into the cell (as the Ca2+ 
channels open at -40 mV), balancing the charge difference and keeping the TMP 
just below 0 mV. Ca2+ channels are gradually inactivated and the outflow of K+ 
returns the TMP to -90 mV. Pumps in the cellular membrane restore ionic 
concentration gradients. The influx of calcium is the mechanistic trigger for the 
Fig 5 Diagrams of action potentials in pacemaker and regular contracting cardiomyocytes. 
Figure from Clinical ECG Interpretation3. 
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excitation-contraction coupling. As documented in the introduction, the initial influx 
of Ca2+ during the plateau in the action potential triggers a much greater release 
of Ca2+ from the sarcoplasmic reticulum; this Ca2+ acts on tropomyosin complexes 
to induce the contraction. 
The ability to gather information on the shape and duration of this action 
potential is important in evaluating electrical health of the heart. Conduction 
velocity on the macroscopic tissue scale presents in the EKG as the time between 
and the time of the P wave (electrical manifestation of the spread of atrial 
excitation), the QRS complex (spread of ventricular excitation), and the T wave 
(repolarization of the heart). Electrical abnormalities are the cause of long QT 
syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular 
tachycardia and the short QT syndrome, which may result in fibrillation, which are 
evident in the EKG readout. Therefore, it is very important to understand how 
an implanted cell source/sheet functions electrically, how this will affect the 
electrical conduction through the heart, and how patient EKG can be 
translated to stimuli for patch conditioning. Here we review the state of the 
art for individual cell and larger cell/tissue culture electrical measurements 
in vitro. 
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2.22 Existing Methods for Electrical Measurements  
Automated Patch Clamp 
Patch clamp is a technique to measure the electrophysiology of single cells 
by placing a hollow glass tube known as a micropipette that contains an electrolyte 
solution and a recording electrode connected to an amplifier into contact with the 
cell membrane. A reference ground electrode is placed in the bath surrounding the 
cell or tissue and an electrical circuit is created with the cell in between. In this way, 
by either controlling the voltage or the current across the membrane, the resulting 
current and voltage respectively can be recorded. There are different placement 
modes of the micropipette tip which result in different measurements of specific 
ion channels or the entire cell6,44. Although the gold standard for 
electrophysiological measurements, the technique is hard to employ due to the 
manual intensity and training required for accurate and consistent performance. 
Today, there are systems in place for automated patch clamp which allow for wider 
application of the technique, removing the operator from micropipette tip 
Fig 6 Traditional (figure from Clare et al.4) vs automated patch clamp setups (figure from 
Long et al.6). 
EXAMPLE OF 
AUTOMATED PATCH 
CLAMP 
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placement and allowing multiple 
measurements in parallel. Most 
automated designs achieve their 
configurations by effectively flipping 
the system upside down, allowing 
cells to attach to a substrate, and 
probing them with the recording 
electrode from the bottom. Today the main application of patch clamp in the 
cardiac world is to screen drugs for their effects on the electrophysiology of the 
heart. The ability to expose arrays of cells to different drugs at different 
concentrations allows for the fast evaluation of potential therapeutics. They are 
also used to evaluate the maturity of stem cells differentiated into 
cardiomyocytes45,46.  
Microelectrode Arrays 
While individual cellular function is crucial for a patch to work, it is also 
important to be able to evaluate the conduction velocity properties of an entire cell 
sheet. This is the value of microelectrode arrays (MEAs). Multi-electrode arrays 
can selectively stimulate cells over a larger area and record their responses. 
Electrodes on the array can stimulate seeded cells by transducing electronic 
currents into ionic currents through the media and electrodes can also transduce 
the change in voltage which results from ion flow through the membrane into 
electronic current for readout47-49. Typical in vitro MEA biosensors usually cover a 
Fig 7 Sample of microelectrode array layout. 
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welled-in square recording area of 700x700 um to 5x5 mm. Roughly 60 electrodes 
are aligned in a grid with inter-electrode distances from 100-500 µm and electrode 
diameters of 10-30 um. A substrate integrated reference electrode is also included. 
By culturing cells on the device, the local field potentials of electrically active cells 
(which can be correlated to the activity of the underlying ion channels) at each 
point across the array area can be measured when cells are exposed to different 
stimulation frequencies, media formulations, and culture/seeding density 
conditions50,51. Array aspects that affect recorded signals include medium in which 
cells are located, degree of contact between the cells and the electrode, electrode 
impedance, electrode noise, and the signal processing setup. Vertical nanowire 
electrode arrays combine aspects of patch clamp and MEA technology. Flexible 
MEAs allow for recording signals from non-planar tissues or cell cultures. 
2.23 Motivation for Mechanical Measurements 
Two reasons the mechanics of cardiac tissue implants should be 
considered are (1) if the construct is beating, it should contribute to and maintain 
the strong, healthy contraction of the heart and (2) whether or not it is beating, it 
should be able to withstand the cyclic strain it will be exposed to during repeated 
heart contraction.  
With regards to criteria (1), native adult human heart tissue is able to 
achieve contractile stresses on the order of 15–30 kPa52. Failure of the heart 
muscle to contract with enough force results in decreased ejection fraction and 
cardiac output. Cardiac output is the amount of blood pumped by the heart in a 
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specific period of time; this is the product of the stroke volume (blood pumped with 
one contraction) and the number of heart beats per minute. For a healthy adult 
heart, cardiac output is around 5 liters of blood per minute. Ejection fraction is the 
percentage of blood in a ventricle that is pumped out with each contraction; this is 
60-70% in healthy adults. As these are decreased, the rate at which the body can 
remove carbon dioxide and other waste products and resupply the system with 
oxygen rich blood is also reduced. A weakly contracting patch can limit heart 
performance. 
With regards to mechanical integrity and compatibility (2), patches should 
be strong and extensible enough to withstand the cyclic motion associated with 
beating. Myocardial tissue is mechanically dynamic53. Shear stiffness during left 
ventricle contraction closely matches chamber pressure during diastole and 
systole, covering a range from 6-10 kPa53. In accordance with the Frank-Starling 
Law, contractile force generated by the heart increases with increasing strain; the 
heart synchronizes cardiac output with venous blood return. Cardiomyocyte 
contractile force scales with volume-dependent ventricle contractile force and 
stroke work due to the coordinated activity of the myocardial syncytium53. 
Therefore, patches implanted need to be compatible with this dynamic mechanical 
environment even if they themselves are not contributing to the motion. Also of 
importance, is the modulus of the tissue at the implant sight. Injury to the heart 
such as myocardial infarction can cause scarring and stiffening of the tissue. It is 
important to understand how the patch mechanical properties should be 
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tailored for best incorporation at the site of implantation.  
2.24 Existing Methods for Mechanical Measurements  
Mechanical forces generated by cells drive the movement of tissues as well 
as the interactions of cells with the surrounding environment. For cell sheets for 
cardiac implantation, the ability to measure beat contractility and or cellular sheet 
tension/uniformity as it is grown is crucial. With this in mind, some of the more 
common techniques for traction force and beat contractility measurement will be 
reviewed. Most mechanical measurements are derived by knowing the mechanical 
properties of linear elastic materials that the cells are seeded on. By tracking the 
displacement of these materials under the applied loads of cells, the material 
Fig 8 Options for traction force and contractile force measurements of cells. Figure from 
Polacheck et al5 
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modulus and geometry of the substrate can be used to extract the amount of force 
that’s been applied in order to deform the material the detected displacement. 
Figure 8 nicely summarizes these different strategies5.   
Micropillar Array Systems and Tissue Pillars 
Individual cellular contractility can be measured by tracking the 
displacements of polymeric micropillar arrays as cells sitting on top bend the 
structures54-56. This technique has been used to study the contractile response of 
non-beating and beating cells56-58. A system related to this idea, but for the larger 
microtissue scale involves two or four larger polymer posts. In brief, 100-600 cells 
can be seeded into a collagen gel surrounding PDMS microposts (appropriately 
sized for applied loads). The cells grow into a tissue that attaches onto the tops of 
the posts59,60. As the microtissue contracts, the larger post deflections are recorded 
with a microscope camera. 
Traction Force Microscopy 
 
Cells are mechanically attached to other cells and surrounding ECM and 
contractile forces are transmitted to these neighbors via cell-cell and cell-matrix 
adhesions. Cellular forces applied to the local microenvironment are known as 
cellular tractions (on the pico to nano-Newton scale). When these small forces are 
applied to soft substrates they can induce measureable material deformation. One 
common technique seeds cells on polyacrylamide gels (which have tunable 
stiffness) and tracks the displacements of embedded microbeads during cellular 
contraction. ECM proteins can be conjugated to the surface. From this quantitative 
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map of material deformation and a well-defined constitutive relation for the 
substrate material, traction forces can be calculated5. 
Tensile Testing of Cellular Sheets 
 
In order to gain information on cell sheet mechanical properties as a whole, 
uniaxial tensile testers capable of detecting milli-Newton forces and applying 
micron scale displacements are used. Cell sheet modulus, ultimate tensile 
strength, maximum strain, and toughness can be determined for full sheets with 
different numbers of cell sheet layers, alignment, and conditioning. This is valuable 
in identifying ways to relate cell mechanical measurements such as traction on a 
substrate to full scale sheet mechanics, especially as it relates to extensibility, 
strength, and cyclic loading. 
2.25 Motivation for Mechanical and Electrical Stimulation  
During embryonic development, the heart starts beating at 22-23 days, 
exposing the cells and tissue to mechanical and electrical stimuli very early on and 
throughout growth of the fetus; the heart is one of the earliest differentiating and 
functioning organs. This is the motivation for creating conditions that mimic in vivo 
stimuli to drive stem cell maturation towards functional equivalency of actual 
cardiomyocytes. Mechanical stimulation via beating (the generation of contractile 
force) and the bulk mechanical stimuli of the tissue affect development and 
function. Basic cellular processes such as protein and gene expression and 
cellular communication are functions of intracellular tension and/or extracellular 
stress61. Mechanical forces also play a role in normal hypertrophic cardiac growth. 
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It is the propagation of electrical signaling via ionic gradients through the tissue 
that trigger the mechanical contraction. Electrically decoupled tissues lead to 
arrhythmias; it is very important that tissue constructs are electrically integrated to 
be compatible with the host tissue. Electrical stimulation can lead to enhanced cell-
cell coupling and improved calcium handling. 
2.26 Electrical Stimulation of Cardiac Cells and Tissues 
Most electrical stimulation setups use two electrodes to provide bulk field 
stimulation to the culture container, directing electrical impulses through the culture 
media. Electrodes are often either made of carbon rods, gold, or platinum wires 
and the stimulation duration, voltage, and frequency can be optimized to improve 
cell differentiation or maturation. Table 1 below summarizes examples from the 
literature that demonstrate the effects of electrical stimulation on cellular 
phenotype and function. 
Table 1 Examples of electrical stimulation. 
Electrical 
Method of 
Stimulation 
Experiment Result Ref 
Gold 
Electrodes 
Culture chip with microgrooves/ridges, 
gold electrodes were placed either 
parallel or perpendicular to the 
grooves, neonatal cardiomyocytes 
(CMs) were cultured for 7 days while 
being stimulated. 
CMs were contractile and aligned 
along microgrooves, CX43 
expression localization near cell-
cell junctions, increased 
elongation for microgrooves 
parallel to electric field. 
62 
Carbon Rods 
Neonatal rat CMs and cardiac 
fibroblasts (CFs) seeded in Matrigel 
onto collagen sponges, continuously 
stimulated for 5 days with electrical 
pulses (rectangular, 2 ms, 5V/cm, 
1Hz). 
Stimulated constructs had 
elevated levels of MHC, Cx43, 
cTnI, greater contraction force, 
increase in max pacing frequency 
that maintains synchronous 
construct contractions. 
63 
Biowire 
Cell laden collagen I gel compacts 
around a suture, forming a wire like 
structure that can be stimulated. 
Increased myofibril ultra-structural 
organization, increased 
conduction velocity, decreased 
excitation threshold, improved 
calcium handling. 
64 
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Monophasic 
vs. Biphasic 
Pulsing 
Monophasic (5V for 2ms, 1Hz) and 
biphasic (+2.5V for 1ms, -2.5V for 
1ms, 1Hz) applied to human cardiac 
progenitors. 
Biphasic resulted in upregulation 
of early cardiac transcription 
factors. 
65 
 
2.27 Mechanical Stimulation of Cardiac Cells and Tissues  
Mechanical stimulation has been performed in 2D and 3D with the following 
three generic methods: varying substrate stiffness, stretching the substrate over 
time, and dynamic stretching and relaxing of the substrate. Cellular alignment and 
sarcomere organization, cardiac gene and protein expression relative to normal 
cardiomyocyte phenotype, calcium transport, and contractility of the 
cardiomyocytes have been evaluated as functions of mechanical stimulation. 
Table 2 below summarizes examples from the literature that demonstrate the 
effects of mechanical stimulation on cellular phenotype and function.  
Table 2 Examples of mechanical stimulation. 
Mechanical 
Method of 
Stimulation 
Experiment Result Ref 
Substrate 
Stiffness 
Neonatal CMs grown on 1,10,50 
kPa polyacrylamide gels. 
CMs had well defined and aligned 
striations on 10 kPa gels 
(embryonic stiffness) and not on 50 
kPa gels (too stiff), also greatest 
action potential on 10 kPa. 
66 
Substrate 
Stiffness, 2D 
Human pluripotent derived 
cardiomyocytes on 4.4-99.7 kPa 
polyacrylamide hydrogels with 
fluorescent beads for tracking 
contractile output in response to 
substrate stiffness. 
Contraction stress of all types 
increased with substrate stiffness, 
no effect on beating rate or 
morphology. 
65 
Substrate 
Stiffness, 2D 
Neonatal CMs were cultured on 
micropost arrays of varying 
stiffness. Optical line scanning was 
used to quantify twitch power. 
Twitch power was greater for cells 
cultured on stiffer posts, improved 
myofibril structure and increased 
calcium levels observed as well. 
67 
Increasing 
Stiffness Over 
Time, 2D 
Chick embryonic heart cells plated 
on hydrogels that stiffened over 
time. 
CMs on stiffening gels had 
increased sarcomere length, 
expression of Nkx2.5 and cTnT as 
compared to static. 
68 
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Static Stretch, 
2D 
Myofibrillar structure of nonbeating 
(contraction blocked) neonatal CMs 
in a 0% static stretch and ones in a 
5% static stretch were compared. 
Contractile arrest resulted in 
myofibrillar abnormalities, but the 
static load appeared to partially 
stabilize myofibrillar structure. 
69 
Gradual 
Stretch Over 
Time, 2D 
Adherent cultures of neonatal rat 
CMs were unidirectionally 
lengthened (25% of original 
length/day) over 2-4 days. 
CM organization into parallel arrays, 
increased binucleation, increased 
hypertrophy by longitudinal cell 
growth, increased MHC protein 
content. 
70 
Dynamic 
Stretch, 2D 
Neonatal rat CMs cultured on 
FlexCell membranes were 
subjected to cyclic mechanical 
stretch (1 Hz, 10%) for 24 hours. 
Stretch induced elongation of CMs 
and accentuation of Cx43 at the cell 
poles, effect could be mediated 
using a focal adhesion inhibitor. 
71 
Dynamic 
Stretch, 2D 
Microarray analysis of papillary 
muscles cultured for 12 hours at 
physiological or reduced level of 
cyclic shortening and stretch. 
Concluded that in intact 
myocardium, amount of cyclic 
shortening regulates myocyte genes 
associated with hypertrophy and 
ECM genes. 
72 
Dynamic 
Stretch, 2D 
ESCs cultured on elastic polymer 
scaffolds were subjected to cyclic 
strain. 
Stretched ESCs had elevated 
cardiac gene expression compared 
to unstrained controls, stretched 
ESCs also had reduced fibrotic 
tissue formation upon implantation. 
73 
Dynamic 
Stretch, 3D 
Neonatal rat CMs encapsulated 
within collagen gels to form tubular 
EHTs that were uni-axially 
stretched. 
After four days, exhibited improved 
CM organization, increased cell 
length/width, myofilament length, 
mitochondrial density, sarcomeric 
alpha actinin, and metabolic activity 
74 
Dynamic 
Stretch, 3D 
Collagen gels anchored at PDMS 
post endpoints, compaction of gel 
by entrapped cells enables 
mechanical stimulation, indentation 
by AFM microscopy tip at varying 
magnitudes/frequencies. 
Enhanced the CM phenotypes, 
improved striations and cell 
alignment, did not affect beating 
frequency, did not influence calcium 
signaling or cellular synchronicity. 
75 
 
2.28 Combined Electrical and Mechanical Stimulation  
It has been repeatedly demonstrated that both electrical and mechanical 
stimulation that mimic the in vivo environment applied in vitro can improve the 
maturation and differentiation of cells towards the cardiomyocyte phenotype.  
Therefore, a recent push has been towards combining both stimuli into 
platforms that allow for physiologically relevant electromechanical timing and 
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application. A few of these systems are described briefly in Table 3: (A)78, (B)76, 
(C)77.  
Table 3 Examples of combined electrical and mechanical stimulation. Figures from Stoppel et al.61, 
Miklas et al.76, and Wang et al.77. 
 
  
30 
Currently, in vivo cellularized cardiac patches do not provide functional 
benefit over existing cell-free patches; this is possibly due to the fact that cells 
are not integrating well upon implantation. Preconditioning tissue constructs 
through controlled exposure of patches to the variability and irregularity of 
stimulation seen in vivo is a promising method to improve patch incorporation 
and functional enhancement61. 
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CHAPTER THREE: PLACENTAL CELL CULTURE AND 
CHARACTERIZATION (AIM 1) 
 
3.1 Motivation to Fabricate Placental Mesenchymal Stem Cell Sheets 
As touched on in the introduction, congenital heart defects are the leading 
cause of birth-defect-related illness and death. One percent of people are born 
with a CHD; twenty five percent of these infants will require surgery within their first 
year2,7,8. Current surgical approaches to ameliorate CHDs include implanting 
synthetic or biological valves, stents, or patches. These can allow patients to 
survive into adulthood; however, rejection of material, inflammation, thrombosis, 
and the inability of the graft to expand with patient growth limits the time before 
reoperation is required. These complications would be reduced by scaffold-less 
tissue patches (consisting of stacked cell sheets to mimic tissue structure) with 
capacity to repair, remodel, and grow. 
 Current surgical patch materials most commonly include synthetics such as 
Dacron and Gore-
Tex and autologous 
and xenogenic 
pericardium79. 
However, as tissue 
engineered 
structures become 
more clinically 
relevant, cell sheet 
Fig 9 Existing patch technology used in surgery today versus two 
developing cell sheet patch technologies for cardiovascular applications. 
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constructs could become routine surgical patch materials as well. Cell sheet 
engineering shows promise in heart surgery via the following patch applications: 
(1) thin cell sheet wraps used as vehicles for stem cell delivery to enhance tissue 
repair and (2) thick constructs for structural replacement of the myocardium. Both 
cell sheet constructs should meet the general criteria for patch materials: non-
thrombogenic, infection resistant, lacking antigenicity, able to grow with the tissue, 
and have long durability79 in addition to the application specific criteria stated in 
Figure 9.  
Both applications require an abundant cell source. As resident 
cardiomyocytes are limited despite some regeneration34, finding another cell 
source abundant enough for patch fabrication is crucial. Many cell sources have 
been considered in the literature for cardiac repair, including cardiac progenitor, 
derived-pluripotent, embryonic, and mesenchymal stem cells10-17. This chapter 
explores placental mesenchymal stem cells (pMSCs) as a source for cell sheet-
based implants. The placenta, traditionally discarded at birth, is an untapped, 
abundant, and readily available cell source. It can be collected at the time of 
delivery for pediatric patients that have been diagnosed prenatally with congenital 
heart defects, making it a promising option for pediatric cardiac repair solutions.  
To evaluate mechanisms for pMSCs to aid in cardiac therapy, I will first 
review MSCs, independent of tissue source, as cells for heart repair and 
regeneration. To date, MSCs have been isolated from many cell sources: bone 
marrow, adipose tissue, umbilical cord blood, dental pulp, amniotic fluid, urine, and 
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more recently, the placenta21-25. MSCs from various tissue sources have been 
shown to differentiate into cardiomyocytes in vitro38-40,80. However, more recent 
research suggests that in vivo1, paracrine secretion and cell-cell interactions by 
undifferentiated MSCs at the site of implantation in the heart are important in 
affecting tissue repair. MSCs secrete factors that induce cardioprotection, 
stimulate angiogenesis, reorganize the extracellular matrix in scar tissue, and 
stimulate migration, proliferation and differentiation of endogenous cardiac stem 
cells1.  
In trials to treat adult myocardial infarction or chronic ischemic 
cardiomyopathy18-20, MSCs from bone marrow, adipose tissue, and Wharton’s 
Jelly have been injected into patient hearts with promising results, including no 
rejection or other adverse effect on resident cells, small improvements to ejection 
fraction and heart contractility, and reduced scarring1. Unfortunately, benefits in 
preclinical studies are still stronger than those in clinical trials. MSCs from various 
tissue sources share many characteristics, but some differences occur due to the 
niche where they originate, culture conditions, and isolation procedures. 
Therefore, to optimize pMSC use for clinical applications, it is important to 
understand how this specific cell source can benefit the heart. 
The primary goal of this study is to determine if and how pMSCs might aid 
in cardiac repair and regeneration by evaluating their phenotype and behavior as 
scaffold-less cell sheets. Cardiac benefit can be realized through the differentiation 
of pMSCs into a cardiomyocyte phenotype or the positive paracrine effects41-43,81 
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of undifferentiated pMSCs on resident cardiac cells. In evaluating cardiac 
differentiation potential, I employ phenotype characterization and compare the 
expression of cardiac-specific proteins before and after differentiation. While I do 
not measure paracrine molecular release, I use in vitro migration and proliferation 
assays to study two common effects of paracrine signaling. The practical, clinically-
driven evaluation of a cell source should also involve three additional criteria: 
cardiac compatibility, cell source availability, and implant deliverability as listed in 
Table 4. This chapter documents promising findings for each criterion. 
Table 4 Criteria for evaluation of cell sources for myocardial repair and regeneration. 
 
In brief, I have isolated MSCs from both chorion and amnion placental 
tissues. pMSC populations have been evaluated for cardiac differentiation and 
their paracrine effects. I have identified the cellular characteristics that pMSCs 
share with cardiomyocytes, suggesting compatibility with resident cardiac tissue 
and confirmed that cell sheets can be formed from pMSCs. I have provided initial 
evidence to support pursuing this cell source for pediatric cardiac regeneration and 
repair solutions. 
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3.2 Materials and Methods 
3.21 Isolation and Culture of pMSCs  
The tissue collection protocol for this study was reviewed by the Boston 
Children’s IRB (IRB-P00007881); it was approved under a discarded and de-
identified tissue sample collection so consent was waived.  Amnion and chorion 
placental tissue from the child side of human placentas was collected from 
caesarean section patients at the time of birth. Tissue was minced into roughly 2 
mm3 pieces and washed with PBS. Five mL of digestion solution (2 mg 
Collagenase II Sigma-Aldrich, St. Louis, MO per mL 0.25% Trypsin-EDTA 0.25%, 
ThermoFisher Scientific, Waltham, MA) was added prior to incubation for 15 min 
at 37ºC. Tissue was washed with media, and transferred to gelatin-coated plates. 
Mesenchymal Stem Cell Media (MSCM: DMEM containing 4.5 g/L Glucose, 10% 
Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin (P/S), 5 ng/mL human 
Fibroblast Growth Factor, ThermoFisher and Sigma-Aldrich) was added to each 
plate to surround each tissue piece, but not cause it to float. Tissue was allowed 
to adhere before addition of more MSCM; cell population grew out from tissue. For 
the total heart cell population, discarded atrial tissue from pediatric surgical cases 
was processed in the same way as the above MSC protocol.  
3.22 Pluripotency Assay – Osteocyte, Adipocyte, Chondrocyte  
Undifferentiated pMSCs were seeded for adipocyte, osteocyte, and 
chondrocyte differentiation according to the Lonza protocols82 (Lonza, Basel, 
Switzerland). Control cells were maintained in MSCM media. After differentiation, 
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cells were fixed and stained for adipocytes (Oil Red), osteocytes (Alizarin Red), 
and chondrocytes (Safranin O) (Sigma-Aldrich). 
3.23 FACS for MSC Phenotype Profile  
The International Society for Cell Therapy definition of MSCs was used to 
evaluate phenotype83. To evaluate pMSC cell surface marker profile, MACS 
Miltenyi Biotec’s MSC Phenotyping Kit was used initially, which characterizes the 
percentage of cells that are CD14-/CD20-/CD34-/CD45- and CD73+/90+/105+ 
(Miltenyi Biotec, Cologne, Germany). Cells were used from both amnion and 
chorion populations for three different patients’ tissues at passage 4. Cells were 
re-suspended at 106 cells per 100 uL FACS buffer. Six control aliquots with 
approximately 105 cells each (isotype cocktail, PerCP/PE/APC/FITC 
compensation, blank) were removed. The remaining cells were stained with 10 µL 
MSC Phenotyping Cocktail per vial for 10 min before 1 mL buffer was added for 
washing. Cells were spun down and re-suspended in 500 uL buffer for analysis 
with the BD FACS Aria II. After analysis of the full profile for these samples, it was 
determined that cells were consistently negative for CD14/CD20/CD34/CD45. In 
subsequent experiments, only the positive markers (CD73/CD90/CD105) were 
used to quantify pMSC percentages per culture using a Guava easyCyte FACS 
machine (Millipore, Burlington, MA). The Miltenyi control cocktail stain was used 
as a control stain.     
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3.24 Cardiac Differentiation  
Standard MSCM was replaced with Cardiac Media (CM: DMEM containing 
1 g/L Glucose, 10% FBS, 1% P/S, 1 mg/mL Insulin, 0.55 mg/mL Transferrin, 0.5 
µg Sodium Selenite, 5 mg/mL Bovine Serum Albumin, 10-4 M Ascorbic Acid, 10-9 
Dexamethasone (ThermoFisher and Sigma-Aldrich))84 and cells were cultured for 
2-3 weeks, changing the medium every 3-4 days as the MSCM was changed on 
the control cultures. Cells were then used for protein harvest for Western Blot 
analysis or re-analyzed with FACS to study if the percentage of cells with the MSC 
profile had changed.  
For Western blots, 25 µg protein were loaded into the gel and run at 100V 
at room temperature for 1.5-2 hours. Gels were transferred to PVDF membrane 
overnight at 4°C and 20V. The membranes were blocked with 5% milk in Tris-
Buffered Saline + 0.1% Tween and then probed with primary antibodies: Anti-
Nkx2.5 antibody [2E1] (1:1000), Anti-Connexin 43 / GJA1 antibody (1:6000), Anti-
Sarcomeric α Actinin antibody [EA-53] (1:5000), various cardiac troponin I and T 
antibodies (Abcam, Cambridge, United Kingdom) and corresponding (Rabbit or 
Mouse IgG) Horse Radish Peroxidase secondary antibodies. Pierce ECL kit 
(ThermoFisher Scientific) and Amersham Hyperfilm ECL (GE Healthcare Life 
Sciences, Marlborough, MA) were used for exposure and development. ImageJ 
was used to quantify bands. For FACS analysis of MSC profile, the same 
procedure from the FACS for MSC Phenotype section above was used. 
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3.25 Cardiac and MSC Migration Analysis 
 Migration studies were performed according to an established protocol85. 
In brief, PDMS stencils with two wells separated by a 500 µm barrier wall were 
plasma-treated, plated and UV sterilized for 30 min. Wells were coated using a 10 
µg/mL human plasma fibronectin solution (Millipore) in PBS solution for 30 min 
prior to cell seeding. pMSCs and cardiac cells were stained with green and red live 
CellTracker stains (Life Technologies, Carlsbad, CA). Each side of a stencil was 
seeded with 21,500 cells of one of three cell types: amnion-derived pMSCs, 
chorion-derived pMSCs, or total heart cell population grown out from discarded 
atrial tissue. Different combinations of these cells were seeded and allowed to 
attach overnight. Stencils were removed from each well, media was added, and 
the gap between cell populations was imaged at 5X with Bright Field, FITC, and 
TRITC illumination (Axiovert S100, Carl Zeiss AG, Oberkochen, Germany).  Forty-
eight hours later, images were taken again. Then cells were fixed with 70% ethanol 
in water at -20ºC overnight and stained with ki67 (primary antibody concentration 
1:200 in DPBS with 10% FBS, secondary antibody concentration 1:400 in DPBS 
with 10% FBS plus 1:200 Hoescht dye for DAPI) to assess pMSC effects on 
Fig 10 Migration assay setup: twelve well plates with one stencil per well that contain 21,500 
cells on either side of a 500μm gap stained with red or green live cell dye. PDMS stencil shown 
in blue is removed after cells attach. Movement of cells is monitored for 48 hours before cells 
are fixed and stained for ki67.  
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proliferation. Wells were again imaged in the same microscope locations at 5X and 
10X. 
3.26 Cell Sheet Fabrication  
Hydrogel substrates for cell sheet fabrication were made according to an 
established protocol86. Lyophilized alginate conjugated with tyramine (Al-ty) was 
reconstituted in Krebs Buffer at a weight-to-volume concentration of 1.5%. A 
patterned PDMS (35um ridges and 35um grooves) was used to cast a gelatin mold 
for the hydrogel solution. The hydrogel solution was mixed with horse radish 
peroxidase (Sigma-Aldrich), deposited onto the tissue culture dish, and the gelatin 
mold was pressed onto the gel to form a patterned surface. The gel was 
crosslinked using a hydrogen peroxide solution87. After crosslinking at 4°C for 10 
min, the gelatin mold was melted away, leaving behind the patterned hydrogel. 
Substrates were coated with Type I collagen (34 ug/ml in 0.02 N acetic acid) and 
washed with PBS and media prior to cell seeding. Cells were seeded at 250,000 
cells/mL of media. The medium was refreshed every 2-3 days until cells were 
confluent on the substrate and ready for release (10 days). For cell sheet 
detachment, the media was replaced with an alginate lyase solution, dissolving the 
substrate and releasing the sheet. 
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3.27 Cell Sheet Mechanical Testing  
For tensile testing of cell sheets, plastic tabs were attached to either side of 
the cell  sheet using super glue and used for mounting the sheet onto a custom-
built uniaxial tensile tester as seen in Figure 1188. Push pins were used to secure 
the tabs to the stretching arm and the flexible beam and samples were stretched 
while submerged in PBS. Once loaded, the cell sheet was lengthened until force 
could be detected at 20% strain.  At this point, calipers were used to measure the 
width and length of the mounted cell sheet. The sheet was conditioned by 
lengthening to 20% strain 3 times at a 
strain rate of 0.0333 mm/s. Sheets were 
then stretched until they broke at which 
point modulus, ultimate tensile strength, 
and max strain could be calculated from 
the stress strain curve, assuming an 
average cell sheet thickness of 30 µm. 
3.28 Statistical Comparisons 
Western blot and migration assay 
data were analyzed using a Student’s two 
sample t-test. A p-value ≤0.05 was 
considered statistically significant. Where 
relevant, a p-value ≤0.1 was indicated.  
Fig 11 (A) Attachment of plastic tabs to cell 
sheet with superglue; tabs are attached such 
that the aligned cell direction is parallel to the 
stretching arm. Push pins are used to secure 
the tabs to the stretching arm and flexible 
beam as indicated by the arrows. (B) Tensile 
stretcher setup. Flexible beams are 
customized to have a stiffness that keeps the 
sensor in the detection range for the applied 
forces. A sample bath allows cell sheets to be 
stretched while submerged in PBS. 
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3.3 Results  
3.31 Pluripotency Assay – Osteocyte, Adipocyte, Chondrocyte 
As seen in Figure 12 (A-C), the pluripotency assay confirmed that MSCs 
are present in the cells cultured from the plated chorion and amnion tissue pieces. 
Fractions of the cell populations isolated from both amnion and chorion were 
differentiated into adipocytes as evident by oil red staining Figure 12 (A) and 
osteocytes as evident by alizarin red staining Figure 12 (B). Chondrocyte control 
pellets did not consistently form; it was hypothesized that this was because they 
did not contain as much extracellular support structure as their differentiated 
Fig 12 Pluripotency assay for (A) adipogenesis, (B) osteogenesis, and (C) chondrogenesis. 
(D) Quantification of MSC-% in pMSC cultures grown out from amnion and chorion tissues. 
Percentages are based on 8 different patient samples.  
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counterparts. Achieved safranin O staining is shown in Figure 12 (C) with the main 
difference between control and differentiated being the absence and presence of 
a pellet. Even with variability in differentiation, there was sufficient evidence of the 
cells’ ability to alter phenotype in order to proceed further with profiling the surface 
markers of the pMSC population and characterizing the population for cardiac 
applications. 
3.32 FACS for MSC Phenotype Profile  
In order to better quantify the MSC fraction and after establishing that cells 
were consistently negative for CD14/20/34/45 surface markers, the 
CD73/CD90/CD105 positive surface marker profile was used to quantify the 
percentage of MSC cells in each population. Total cell populations grown out from 
Fig 13 (A) Sample Western Blot (WB) analyses of amnion and chorion cultures grown in MSCM 
(control) vs. CM (differentiated) media. (B) FACS showing downward shift in the number of cells 
fitting the MSC profile when cultured in CM media. (C) WB quantification for changes in protein 
expression for Nkx2.5, Connexin 43, and Sarcomeric α Actinin. Also shown is the change in 
MSC-% makeup.  
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tissue in MSCM contained 43±26% MSCs from chorion and 49±25% MSCs from 
amnion. An example of the FACS fluorescent profiles used for quantification is 
shown in Figure 12 (D). The yield seems variable and independent of tissue type 
(amnion versus chorion); variability may be due to differences in tissue process-
ability across patient samples.  
3.33 Cardiac Differentiation 
CM differentiation treatment and subsequent protein quantification did show 
a more consistent shift in cardiac protein content. Two amnion and two chorion 
samples were simultaneously cultured in the control MSCM and the CM medias. 
At the end of the culture time, FACS showed the ratio of cells fitting the MSC 
surface profile for CM as compared to MSCM was 0.30±0.19, suggesting that 
some of the MSCs originally present had changed cell type as shown in Figure 13 
(B). Western Blot protein quantification also showed an increase in the expression 
of Connexin 43 (1.7±0.86 ratio of CM:MSCM for the sum of the bands, 1.2±0.24 
for the primary band)89 and Sarcomeric α Actinin (2.2±0.25 ratio of CM:MSCM for 
the primary band) for these cells as shown in Figure 13 (A); both of these proteins 
are characteristic of cardiomyocyte phenotype expression90. There was also a 
coincident decrease in the expression Nkx2.5 (0.36±0.12 ratio of CM:MSCM for 
the primary band). Typically, Nkx2.5 is expressed in cardiac progenitor cells prior 
to differentiation and in mature cardiomyocytes91; a negative shift in this protein 
could indicate a shift towards a non-cardiomyocyte muscular phenotype as the 
level of Nkx2.5 is not maintained.  
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Interesting to note is that the cells without treatment inherently contain 
important cardiac proteins. This is not surprising as it is documented in the 
literature that the placenta inherently contains Nkx2.592, Connexin 4393, and 
Sarcomeric α Actinin94. This is supported by our Western Blot data. The decrease 
in the percentage of MSCs as well as the increase in Connexin 43 and Sarcomeric 
α Actinin suggest that these cells may be shifting towards a more muscular 
phenotype with the CM media treatment. All differentiation data is summarized in 
Figure 13 (C). While mature cardiac phenotype was not produced, it is possible 
that protocols involving functional stimulation might result in more advanced 
cardiac phenotype. 
3.34 Cardiac and pMSC Migration Analysis 
pMSCs seem to enhance the migration and proliferation of cardiac cells 
according to this assay. Qualitatively, it appears that the placental cells draw the 
heart cells in, incorporating them into their side of the culture whereas when the 
heart cells are placed next to heart cells, there is migration to a point, but limited 
integration of the two sides. The following calculation for relative cell movement 
was used to quantify this movement: 
Relative Cell Movement=
Final Cell Area-Original Cell Area
Original Cell Area  
Heart cell movement when placed next to pMSCs was significantly greater 
than when placed next to cells from the same heart cell population as evident by 
a 0.82±0.15 and 0.85±0.21 relative movement score for heart:chorion and 
heart:amnion wells vs. a 0.64±0.14 relative movement score for heart:heart wells 
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as seen in Figure 14 (A). In addition, when these same migration images were 
analyzed for proliferation, the percentage of total nuclei that stained positive for 
ki67 was 16% for pMSC:heart wells as compared to 10% for heart:heart wells as 
seen in Figure 14 (B). While these are only initial in vitro tests for evaluating 
paracrine activity, this data suggests that the pMSCs positively affect the migration 
and proliferation of heart cells. 
Fig 14 (A) Sample images from a migration assay where cells were shown at the 0 and 48 hour 
times points. Quantification of relative cell movement. (B) Sample of migration assay fixed and 
stained for ki67 after 48 hours. Atrial cells that had moved into the gap stained positive for ki67, 
suggesting enhanced proliferation as compared to the heart next to heart assays as seen in bar 
graph.  
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3.35 Cell Sheet Fabrication and Characterization  
After 10 days in culture, both amnion and chorion cell sheets had reached 
confluence, were aligned with the patterned hydrogel substrates, and released. 
Four different patients’ amnion-derived cultures and 3 different patients’ chorion-
derived cultures were used on the same substrate types. At least one complete 
sheet was formed for 2/4 amnion and 3/3 chorion samples; the amnion cultures 
that did not form complete sheets had cell sizes that had trouble bridging the 
groove ridge architecture. It is believed this problem could be resolved by tailoring 
hydrogel substrate groove ridge profiles to better match specific patient cultures’ 
cell shape and size. Cell sheets were viable and aligned upon release from their 
substrates as seen in Figure 15 (A). Complete, stable cell sheets were then used 
for mechanical testing; unfortunately, many fragile sheets were damaged during 
Fig 15 (A) Bright field and live/dead staining for cell sheets, showing linear patterning and 
cell survival pre- and post- release. (B) Number of patient-derived cell populations that 
actually formed sheets. Mechanical data for cell sheet tensile testing: representative 
stress-strain curve for chorion (blue) and amnion (red). (C) Average tensile data for one 
chorion cell population (n=3 sheets). 
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loading. Therefore, only enough data was collected for one chorion sample to 
calculate mechanical properties. One sample chorion (blue) and amnion (red) 
curve are plotted in Figure 15 (B). Most important to note is how the Cauchy stress 
versus strain behavior accurately mimics the anisotropic behavior of human tissue, 
increasing modulus with increasing strain. While the initial (over 0-10% strain) and 
final (over 90-100% strain) modulus vary greatly between samples, the final 
modulus is consistently greater than the initial. For chorion mechanical results, the 
modulus ranged from roughly 8-32 kPa, average ultimate tensile strength was 
17.9±2.92 kPa, and the average maximum strain was 0.93±0.10. Native 
myocardial tissue has a modulus from 20 to 500 kPa95 over the beat cycle, 
meaning these pMSC sheets would require increased stiffness in order to replace 
the tissue. If the cell sheet is to be used as a vehicle for cell delivery, the stiffness 
can be at the lower end of the physiological range (which is nearly achieved by 
these sheets); cell sheets for structural repair should be compatible with the higher 
end of the physiological range95. Modulus and UTS can be increased to 
physiological range by culturing sheets for longer and adding ascorbic acid to the 
culture media96.  
3.4 Discussion of pMSC Findings and Next Steps 
In order to discuss the findings in this study, it is important to revisit the 
criteria established for benchmarking pMSCs as a valuable cell source for 
myocardial cell sheet fabrication and implantation. Based on the results presented, 
pMSCs offer a cardiac benefit in their undifferentiated form through encouraging 
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migration and proliferation of surrounding cells, show potential for cardiac 
compatibility, are readily available, and are compatible with scaffold-less cell sheet 
technology as summarized by the findings in Table 5.    
Table 5 Evaluation of cell source requirements explored. 
 
Demonstrating the ability to form cell sheets from pMSCs is an 
advancement for the field of MSC cardiac therapy. Trials where suspensions of 
MSCs are injected into damaged areas of the heart often present underwhelming 
results.  These studies hypothesize that poor retention97 as a result of blood flow 
causes decreased effectiveness in vivo. Cell sheets eliminate the problem of 
retention as all cells remain at the site of implantation. In addition, because cell 
sheet technology is completely biological (no synthetic scaffold), it has the potential 
to be fast-tracked clinically. As pioneers of cell sheet technology, the Okano group 
sought to overcome many of the barriers to clinical use by using cell sheet 
technology for tissue engineered patches.  After establishing the technology in 
199830, today Dr. Okano has helped create a clinically available cardiac patch in 
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Japan, HeartSheet by Terumo Corporation. The patches made of autologous 
skeletal myoblast sheets treat chronic ischemic heart disease.  We envision a 
similar option from undifferentiated pMSCs with the benefit of a large and non-
invasively available source of cells. 
Returning to Figure 9 from the introduction, the current status of the pMSC 
work places these cell sheets in category (1), a vehicle for stem cell delivery 
intended to recruit resident cardiac cells for tissue repair. Cell sheets are less stiff 
than heart tissue, but still should be compatible and able to adhere and incorporate 
into the existing tissue. However, this does not exclude these cell sheets from 
being driven towards category (2) applications. As noted in the results, with more 
advanced differentiation protocols that involve stimulation, cells could be driven 
closer to cardiomyocyte phenotype and function. There is also technology in place 
to enhance cell sheet modulus and UTS with the addition of ascorbic acid to the 
culture media and increased culture time96. pMSC cell sheets could be stacked 
with themselves or other cardiac-relevant cell source sheets to form a thick, 
electromechanically compatible tissue. At this point, suture tear strength and burst 
pressure of the patch would also need to be evaluated. 
Demonstrating that the cell source will have a clinical benefit (beyond its 
ability to form a sheet) upon implantation is also important. As discussed in the 
introduction and confirmed by migration/proliferation experiments presented 
above, clinical benefit of MSCs reaches beyond differentiability. MSCs possess 
unique characteristics that improve cardiac function such as cell recruitment, 
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promotion of angiogenesis, and immunoprivilege. Additionally, placenta-derived 
MSCs have better proliferation and plasticity than adult cells without the ethical 
and safety issues of embryonic stem cells98. It is not known whether pluripotent 
stem cells persist beyond the first few weeks of embryonic development, but it has 
been shown elsewhere that the placenta in general contains multipotent stem cells 
that express various embryonic stem cell markers including c-kit, OCT4, SOX2, 
SSEA3, TRA-1-60, and TRA-1-8198. The amnion membrane contains amniotic 
epithelial cells derived from the epiblast and amniotic MSCs derived from the 
hypoblast and the chorion contains trophoblasts derived from the outer layer of the 
blastocyst and chorionic MSCs; this ties this cell source closer to embryonic 
development than other MSC sources98. As far as yield of available MSCs, large 
variations in cell harvests make it difficult to compare absolute numbers of cells. 
However, reviewed research reports the highest concentration of MSCs from 
placental tissue99.  
Based on pMSCs’ ability to form cell sheets and evidence here and 
elsewhere for cardiac benefit, studies going forward should evaluate the best 
strategies for employing both sorted pMSC and unsorted total placental cell 
populations (undifferentiated form) in cell sheet fabrication and further evaluation 
of their functional (not just phenotypical) compatibility with the heart. While a pMSC 
population based on surface markers could be identified in all cultures grown out 
from tissue, there was high variability in the yield. In the future, cultures should be 
standardized to control the ratio of MSC to other cell populations across samples. 
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This could be done by sorting pure MSCs and only expanding this population. 
Fibroblasts could be optimally blended in to the pure population to provide 
structural support through extracellular matrix production100 or endothelial cells to 
aid in vascularization101,102. The focus should be to optimize cell sheet fabrication 
for repair and regeneration at the implant site, mechanical compatibility with the 
myocardial wall and motion of the heart, and non-interference with the electrical 
conduction system. Current pMSC cell sheet system limitations include the inability 
to form structures other than patches, no vascularization, and thin constructs that 
make suturing difficult.   
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CHAPTER FOUR: FABRICATION OF BIO-MEMS DEVICE (AIM 2) 
 
Having a stimulation system to 
characterize and condition cell sources 
for myocardial cell sheets such as 
pMSCs was the motivation for the work 
discussed in the next two chapters. 
There are several existing techniques 
for both mechanical stimulation and 
cellular force measurement as well as 
electrical stimulation and conduction velocity measurement as highlighted in the 
literature review. Individual cellular contractility can be measured by tracking the 
displacements of polymeric micropillar arrays as cells sitting on top bend the pillar 
structures. Multi-electrode arrays stimulate cells and record their responses. In 
addition to these and other bio-MEMS for characterization, it has also been 
documented in the literature that mechanical and electrical conditioning of cellular 
constructs can result in tissue remodeling, cellular alignment, increased cardiac 
protein expression, and improved compatibility and incorporation into the body 
upon implantation76,103-106. I designed a new device that allows for both electrical 
and mechanical characterization and conditioning on one platform, such that not 
only can the user selectively stimulate areas of a myocardial cell patch, but also 
monitor the effects on functional outcome. In theory, this provides a powerful 
stimulation and sensing tool to functionally characterize cellular sheets and 
Fig 16 Initial sketch of device design. 
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improve implant success through conditioning prior to implantation. The device 
described herein allows for the evaluation of contractile force and conduction 
velocity of cell sheets in response to mechanical and electrical stimulation of the 
cell source as it grows into a cellular sheet on the device. This allows cell sheets 
to be cultured and conditioned to be compatible with the patient’s cardiac 
environment in vitro, prior to sheet release and implantation. This chapter 
describes device design and fabrication. Major innovative elements of this device 
include: real-time data for rich understanding of engineered tissues as they are 
grown, ability to expose engineered tissues to patient-derived stimuli (specifically 
localized electrical stimuli and micro-architecture), and the option to implant after 
characterization.  
4.1 Theoretical Design 
4.11 Design Criteria 
The initial design criteria for the device are outlined in Table 6. Each 
criterion can be theoretically realized in the device if the geometry, patterning, or 
coating in the appropriate fabrication process can be achieved (column two). The 
final column describes the intended validation test, covered by aim 3 (Chapter V). 
Table 6 Design criteria for device. 
Design Criteria Realization in the Device Validation Testing 
Cell survival and 
alignment on the device 
Surface conducive to 
cell attachment and 
spreading; patterning 
that causes cells to 
align 
Confluent, healthy cell 
sheet grown on device 
Readout of cell sheet 
contractility 
Bending element is 
displaced enough under 
Detection of wall motion 
due to cell contractility 
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cellular force such that it 
can be detected in the 
microscope 
using microscope and 
subsequent image 
tracking 
Readout of conduction 
velocity 
Signal input into one 
electrode can be 
detected at another 
electrode 
Measured physiologically 
relevant conduction 
velocity across device 
Electrical stimulation Electrodes patterned on device 
Stimulation over time 
without killing cells 
Mechanical stretching Pliable substrate that can be pulled 
Stretching synchronized 
with electrical stimulation, 
cell survival over time 
Ability to implant cell 
sheet that has been 
characterized 
Apply oligopeptide 
technology to gold 
Apply hydrogel release 
system in between walls 
Release cell sheet from 
device alive and 
undamaged 
 
In brief, the device achieves these design criteria through the following 
setup. The platform is based on a set of interdigitated comb electrical contacts. 
These are three dimensional walls made of polydimethylsiloxane (PDMS) coated 
with electrically conductive films of titanium (adhesion promotion film) and gold. 
Not only do the walls serve as a method for stimulating cells that are sitting on top 
of them, but their geometry can be tailored to make them flexible enough to be 
bent by the shear forces applied by the cells during contraction. In this way, they 
can be used to measure force throughout the cell culture. The walls also play the 
role of a substrate that has an effective modulus more relevant to muscle cell 
culture than tissue culture plastic or planar PDMS; substrate stiffness has been 
shown to affect cell morphology and phenotype107. The entire platform is flexible 
and can be stretched via a linear actuator setup, allowing for simultaneous 
electrical and mechanical stimulation. 
  
55 
In order for the device to function, it is crucial that there be a method for 
predictably aligning the cells perpendicular to the walls/contacts of the device. This 
is to (1) mimic myocardial cellular architecture, (2) allow a current flowing from the 
positive comb finger contact to the negative comb finger contact to pass through 
the cell (effectively stimulating it), and (3) if cells do contract, they are able to move 
the wall for a mechanical readout. In order to align the cells, a groove/ridge pattern 
is used on the tops of all walls such that the cells orient themselves perpendicular 
to the walls. It has been shown in the literature that cells can be aligned by 
micropatterning the surface on which they are cultured108,109. In this design, the 
ridges are short in comparison to the wall height and assumed not to affect the 
motion of the walls. A 3 mm high PDMS square well is attached to the device to 
isolate cells and media on the comb platform. Electrical connections are made 
outside of the well. 
4.12 Timoshenko’s Bending of Plates for Design of Correct Wall Geometry 
In order to tailor the geometry to have the correct mechanics to be 
compatible with cellular 
forces, theoretical 
calculations and Comsol 
simulations were run to 
determine the wall 
geometry for bending. For 
the following hand 
Fig 17 Case of Timoshenko Bending of Plates: point load 
applied to top of plate, max displacement at x=0. 
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calculations, a modulus of 750 kPa and Poisson’s ratio of 0.49 were used for 
PDMS mixed at a 10:1 ratio and cured at 80°C for 4-12 hours. It is necessary that 
the force applied by cellular contraction move the wall enough that it’s 
displacement is detectable by the microscope. For the standard pillar contraction 
measurement and many measurements that involve bending, the deflecting 
component can be treated like a cantilever beam undergoing small displacements; 
this means that simple beam bending assumptions can be applied when solving 
the Euler-Bernoulli beam equation. However, these equations cannot be applied 
to an infinitely long wall where shear becomes a factor. In the simplest terms, a 
greater force is needed to displace a section of the wall (width and breadth equal 
to the diameter of a cantilever beam) as much as the cantilever beam is displaced. 
Timoshenko’s theory for the bending of plates and shells can be applied to this 
situation110. 
First, in order to relate the displacement of the wall to the force applied, the 
case shown in Figure 17111 was considered; here a point load is applied to the top 
of a wall that is simply supported on 3 sides, with one edge free where the load is 
applied. The maximum displacement at point x=0 where the load is applied has 
been solved to be the following: 
δmax=
αFb2
D  where D=
Eh3
12(1-ν2)   
α=0.155 for point loads applied at top of wall as ba  approaches zero 
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However, this does not accurately represent the bending occurring in the 
case of the polymer wall. In this equation, the entire top edge of the wall is assumed 
to move rigidly and displace the same amount along the entire length. Therefore, 
as the length of the wall approaches infinity, the equation calculates zero 
displacement even at the location of the applied load.  
To better represent the wall motion seen in the device, the theory of bending 
for circular plates was applied instead; this is also described by Timoshenko110. 
The bending of a segment δα of a circular plate which is fixed at the circumference 
and where the load is applied to the center is an exact representation of a similar 
segment of the wall motion because there is no radial direction displacement of 
the point at the center where the load is applied. The material deforms such that 
the central point only moves in the y-direction as seen in Figure 18; the same 
Fig 18 Representation of the bending of the wall under an applied point 
load as the bending of a circular plate. 
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motion is applicable to a point on the wall that it is assumed not to deform in the 
direction along the height of the wall. In applying the circular plate displacement 
equation to the wall, we can treat each segment of the circular plate as a triangular 
beam with base = radius x δα , where the radius is equal to 𝐿𝐿
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
. Using the 
maximum displacement equation for the case of a plate with a concentrated center 
force and clamped edge, integration for the wall can be performed over the angle 
(0 to π), which represents the full length of the wall, to derive an equation relating 
force and displacement as follows: 
 
δ=
Fa2
16πD  where D=
Eh3
12(1-ν2)   
F=
16πDδ
a2
  
For each segment dα: 
dF=
8πDδ
�
L
cosα�
2 dα 
�dF =�
8Dδdα
�
L
cosα�
2
π
0
=�
8Dδcos2αdα
L2
π
0
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8Dδ
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π
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2�=
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F=
8π2Eh3δ
12(1-ν2)L2   
E=
12�1-ν2�L2F
8π2h3δ
 
 
Applying this formula, we see that for a minimum detectable wall 
displacement by the microscope of 0.5 µm, the combinations of contact wall height 
and width seen in Figure 19 will only allow for detection of the minimum force 
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values plotted in (A). Assuming a maximum 10 µm gap in between walls, the 
maximum detectable force value is then plotted based on a 5 µm wall displacement 
(B). Gaps larger than 10 µm allow too many cells to fall in between the walls during 
seeding and the device can no longer function as designed. 
 
δ=
12�1-ν2�L2F
8π2h3E
 
4.13 Confirming with Comsol Simulation 
This predicted deflection was confirmed with Comsol simulation. In the 
Comsol model, the PDMS values of 750 kPA and Poisson ratio of 0.49 were used 
according to the program’s material profile. A force of 20 nN was applied as to 
simulate the lowest possible force applied by a beating single cell. One wall was 
modeled in the 3D Solid Mechanics Stationary mode. The wall was fixed at the 
bottom and side edges; an edge load was applied at a point across the wall. The 
deflection predicted by the simulation is larger than that predicted by the hand 
calculation. Images from different Comsol configurations (applied loads and 
Fig 19 (A) Minimum detectable force in µN with the given wall geometry as set by the 
minimum microscope detection of 0.5 µm. (B) Maximum detectable force for a maximum 
displacement of 5 µm as set by a maximum gap between walls of 10 µm. 
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geometries are shown in Figure 20). The max displacement values as predicted 
by the circular plate model and the Comsol simulation are shown in Figure 20 as 
well. 
4.14 Confirming with Macroscopic Experiment  
In order to visualize the profile of the wall motion and to confirm that the 
equation derived above was representative of the force displacement relationship, 
a macroscopic version of the device was created. Two walls made out of PDMS 
(2.5x16x76 mm and 2.2x15x76 mm) were mounted onto glass slides. A thin, 
effectively massless string was attached to the middle of the top edge of the wall 
using super glue and the glass slide was mounted onto a metal plate as depicted 
in Figure 21. The string was extended over an equally tall metal wall barrier at the 
Fig 20 Comsol simulations and maximum wall displacements. 
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end of the plate, where masses could then be loaded onto the end of the string. 
The displacement of the wall top under different mass loads was imaged using a 
microscope. Using the displacement vs. mass (force) data for two different 
macroscopically representative versions of the device wall, an average modulus 
could be calculated using the bending plate equation from above; this was 
compared to the published modulus value of PDMS, 750 kPa. The average 
modulus calculated from the equation derived from the bending of a circular plate 
Fig 21 Macroscopic validation of wall motion and calculated displacement values. 
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was 2.3 times that of the published value for PDMS. Visually, motion agreed with 
the Comsol simulated displacements. 
 4.2 Fabrication of the Device  
After many iterations of designing the device in different materials and with 
different geometries, a fabrication strategy was developed that is quick, 
reproducible, and successful in providing all components necessary for the 
functional evaluation of cell sheets for myocardial applications. In brief, the 
fabrication steps include preparing an auxiliary silicon mold using established 
photolithography techniques, casting the polymer PDMS into the mold to create 
the three-dimensional grooved interdigitated comb-wall architecture, coating the 
top of this device with conductive (standard titanium/gold) film, and finally attaching 
a well for cell isolation and wires for electrical stimulation and readout. In the 
following sections, the device fabrication steps will be discussed as well as the 
accompanying microscope and oscilloscope setups for stimulation and readouts.   
4.21 Silicon Mold Design  
There are two masks necessary for processing, whose geometries are 
based upon cellular properties: the groove mask which is used for cellular 
alignment across the electrical contacts and the contact mask, which sets a gap 
between the contact walls as well as the width of the contacts. Standard 100-mm 
wafers are used for mold fabrication; each wafer can fit 12 devices, each with a 
1x1 cm sensing area surrounded by a 100 µm border for well attachment.  
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Groove/ridge patterns, used for cellular alignment are created first; initially 
grown silicon dioxide film is used as a mask in the standard 45% KOH solution for 
groove etching. The next step is applying the contact mask such that the walls are 
perpendicular to the grooves. First, the wafer is patterned with AZ4620 on top of 
the groove profile by spinning on HMDS primer and then resist. Wafers with resist 
are then baked in an oven at 90ºC, exposed on the Hard setting of the MA6 Mask 
Aligner, developed in AZ400K, and hard baked at 120ºC prior to a Bosch deep 
reactive ion etch (DRIE) step. The ranges of dimensions listed in Table 7 were 
fabricated and tested with cells. The two step pattern design allows the angle 
between the groove/ridge pattern and the contact walls to be altered. In future 
designs and experiments, cell alignment from 45-90º from wall direction may be 
desired. 
Fig 22 Fabrication scheme for bio-MEMS device. 
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Table 7 Range of geometries fabricated in devices. 
Component Dimension (µm) 
Wall Width 5-50 
Wall Spacing 10-50 
Wall Height 35-100 
Groove Width 10-90 
Ridge Width 10-90 
Groove Depth 5-15 
 
The relative dimensions can be changed for different cell types and 
applications, but the following attributes should be preserved in the design: 
-Overall device area: 1 cm2. This will eventually need to be scaled up for 
physiologically relevant patch sizes, but for prototype design and cell source 
evaluation, this footprint is sufficiently large and allows for the efficient 
casting of 12 devices with one 4” wafer mold as seen above. 
-Ideally comb electrical structure with distances no more than 10 microns 
between combs such that the number of cells that fall into the gaps is 
minimized (as the approximate diameter of a balled up cell is 10 microns), 
but no less than 5 microns such that walls have space to bend for 
microscope detection without hitting adjacent walls. Larger gaps were 
realized in late stage design during device validation; this method will be 
discussed in the next chapter. 
-The groove/ridge width should be narrower than the wall width. In order to 
encourage micro-architecture characteristic of the heart and to be able to 
stimulate cells with the comb contact configuration, it is necessary that most 
cells align perpendicular to the comb contact or wall pattern. However, as 
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discussed in the 
results section, it 
was discovered that 
if the wall pattern is 
significantly narrower than the groove/ridge pattern, the cells choose to 
align with the wall features, which is 90º opposite of the desired direction. 
By reducing the groove/ridge width to less than that of the walls, more cells 
aligned in the proper direction. 
-It should also be taken into consideration that the KOH etch occurs at a 
rate 100 times faster in the <100> direction as opposed to the <111> 
direction, creating an angled etch at a 54.7º. Therefore, as silicon groove 
patterns become narrower and deeper, resulting PDMS ridges become 
pointier. Width loss can be accounted for by oversizing the exposed groove 
area in the mask design.  
Width Loss=2*
Etch Depth
tan(54.7°)  
Fig 23 Etch profiles for KOH. 
Fig 24 SEM images of silicon molds for PDMS casting. 
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The Resulting Devices section discusses the advantages and 
disadvantages of different geometries, but important to note is the ability to tailor 
geometry to specific cells types and applications. One important feature of the wall 
etch for this device is creating negative sloped side walls in the silicon mold that 
result in negative sloped slide walls in the PDMS cast; this was achieved by using 
a more aggressive etch during the DRIE process. These slightly negative sloped 
side walls on the PDMS prevent shorting of the 2 comb electrodes during metal 
deposition. The opposite effect for groove/ridges allows for continuous gold 
deposition across the top of a wall. 
Fig 25 Zygo image of a silicon mold showing groove ridge patterning on top of walls. 
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4.22 PDMS Casting  
As soon as the DRIE 
process is completed, wafer 
molds are cleaned in acetone, 
then Piranha; the mold is 
silanized for at least 2 hours 
prior to PDMS casting; 
approximately 10 µL of 
silanizing agent is put on the bottom of a Petri dish and placed under vacuum with 
the wafer.  PDMS is mixed in a 10:1 ratio of polymer to curing agent and poured 
onto the mold. Prior to baking, the mold with uncured PDMS is placed in a 
desiccator under vacuum for at least 30 minutes to remove all air bubbles trapped 
within the micron-scale features of the mold. It is then baked at 80°C for 4-12 hours. 
Once PDMS is peeled off from the mold, each device is cut out individually and 
placed onto half of a glass slide. An electron beam evaporation system is used to 
deposit a thin layer of titanium and then 
gold while a foil mask on either side of the 
device is used to prevent deposition 
between the contact pads and avoid 
electrical shorting. If performing 
conduction velocity experiments, bands 
across the middle of the device can also Fig 27 Checking for shorting after Ti/Au 
deposition on device. 
Fig 26 Devices that have been shadow masked with foil 
and tape prior to Ti/Au deposition. 
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be masked off. Foil masks can be 
applied by cutting the desired area to 
be blocked out of foil and securing in 
place with tape. After metal deposition, 
devices are un-taped and checked for 
shorting by using a multimeter to measure the resistance between the two contacts 
and between sections separated for conduction velocity measurements as seen in 
Figure 27. 
A PDMS 3 mm high square wall is then attached to isolate the 
stimulation/measurement area from the contact pads. A Teflon mold was designed 
in CAD for fast casting of well walls with the correct dimensions. Wires are attached 
to the contact pads with a silver epoxy, device is sterilized with ethanol, and oxygen 
plasma treated for 45 seconds. A 10 µg/mL fibronectin in PBS1X solution is used 
to coat the device with protein for 30 minutes before cells are seeded and allowed 
to attach overnight prior to testing. 
4.3 Resulting Devices 
Devices were fabricated with different combinations of wall width and height 
and groove/ridge width and height within the ranges stated in the earlier table. The 
mold that ultimately allowed for cellular alignment on top of the device was the 
“5010” device; it had a wall width of approximately 45 µm, gap between walls of 10 
µm, ridge and groove base width of 10 µm, wall height of 35 µm, and ridge height 
of 6 µm; this is referred to as the good alignment mold. All other (bad mold) 
Fig 28 Mold for wells. 
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configurations had poor or inconsistent cell growth on top of the device and 
therefore, poor alignment. However, 50 µm wide walls need to be taller than 35 
µm in order to flex under applied cellular contractility forces. Ultimately taller, 
skinnier walls were needed for mechanical force measurement validation. This 
iteration on device design is discussed in the next chapter. Here, a sample of the 
Fig 29 Top: Examples of geometries created in PDMS. Bottom: Motivation for negative 
sloped side walls for PDMS contacts and positive sloped side walls for groove ridge profile. 
* 
  
70 
different geometry combinations are presented in Figure 29 below. These 
demonstrate (1) how different micropatterning for alignment can be created by 
combining different ridge/groove widths with different KOH etch depths and (2) 
how the negative slope walls can be consistently created.  
4.4 Fabrication Attempts in Silicon 
The original sketch of the design is shown in Figure 16, taking an 
established microelectrode array and fabricating pillars on top. In order to allow for 
stimulation, the pillars could be fabricated from conductive polymer or silicon. 
Altering the mechanical and translucent properties of PDMS while trying to dope it 
to be conductive were deterrents for attempting to revamp the current micropillar 
technology in a conductive polymer. Also, attachment of conductive polymer pillars 
to existing MEAs without shorting the devices seemed unlikely. Therefore, original 
devices were attempted using silicon, as it can be doped for low resistance, high 
conductivity and the microfabrication tools established in standard clean rooms are 
optimized for silicon processing. However, there are many problems related to 
inflexibility, bonding of the pillar to the 
microelectrode layer, and cellular incompatibility 
that ultimately prevented this design from being 
realized. However, during development, several 
fabrication skills and techniques were 
developed. I will highlight these here even 
though they did not end up in the final design. 
Fig 30 Silicon aspect ratio as a 
function of cellular force applied. 
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4.41 Pillar Fabrication 
The challenge with building a micropillar array platform in silicon is the 
extreme aspect ratio required to produce pillars that have detectable 
Fig 31 Top: SEM images of silicon pillars. Bottom: Optical microscope 
image of pillars. 
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displacements. A single micropillar being acted on by a cellular force is usually 
modeled as a cantilever beam. The displacement of the pillar top as a function of 
the force applied, modulus of the material, and geometry of the pillar can then be 
calculated as follows:  
δ=
64FL3
3πED4
 
The modulus of silicon is 150 GPa, 200,000 times that of PDMS. This 
means that in order to create pillars flexible enough to be bent by an assumed 
cellular force of 20 nN and have a detectable displacement of 0.5 µm, the aspect 
ratio would need to be roughly 82. I was able to etch pillars with an aspect ratio of 
roughly 20:1. SEM images below show the structure of fabricated pillars. In brief, 
low resistivity silicon wafers were oxidized at 1600°C for 10 hours. S1805 
Photoresist was deposited at 4000 RPM and a pattern of 5 µm diameter circles 
with 7.5 µm center to center spacing was written using the DWL66 Mask Writer. 
After development, oxide was etched in BOE and then a DRIE Bosch process was 
used for pillar fabrication. The time of the C4F8 passivation and SF6 etching steps 
as well as the number of cycles was varied to determine an optimal combination 
of etching and passivation that resulted in tall pillars with limited wall taper. Sample 
SEM images of the pillar array for the 8 second etch, 3 second passivation, 120 
cycles are shown in Figure 31. Uniform, standing pillars were achieved; pillar 
diameter after etching was 1 µm less than original patterning. Straight enough side 
walls to support the tall pillar structure were also achieved. 
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4.42 Layering Sensing Components 
In order to bond the rows of pillars to the electrodes below, several layering 
schemes were considered as seen in Figure 32. Challenges with layering included: 
bonding such that groove and ridge architecture was preserved, bonding was 
achieved without destroying pillars, all excess conductive silicon could reliably be 
removed, and no detachment occurred after bonding. Some of these schemes 
require two patterning steps. While this is usually achieved with cross-hatch marks 
in both patterns that can be aligned in the mask aligner prior to exposure of the 
second pattern, the DWL66 Mask Writer Laser was used to achieve better pattern 
resolution. Therefore, alignment of the second pattern has to be achieved by 
keeping track of the detected plate centers in the first and second patterning; by 
offsetting the pattern with the difference in centers, correct overlap of the two 
Fig 32 Layering strategies for pillars with electrodes. 
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patterns was realized. Bonding of silicon pillars was not attempted, but based on 
handling of pillars and bonding methods, both preserving structure and ensuring a 
strong bond seemed very challenging. At this point, the parallel technology in 
PDMS had showed more promise and so all focus was switched to developing this 
for cell compatibility and testing.  
  
75 
CHAPTER FIVE: VALIDATION OF BIO-MEMS DEVICE (AIM 3) 
 
In order to validate that the fabricated devices could meet the initial design 
criteria, the following setups, cellular experiments, and electrical/mechanical 
measurements were performed.  
5.1 Setups for Stimulation and Measurement 
5.11 Electrical Stimulation 
For the work described herein, two stimulation modes were used as seen 
in Figure 33: direct contact to contact (left) and contact to common ground (right). 
In direct contact to contact, an electrical pulse generated by a function generator 
is applied to the sets of comb electrical fingers. The signal wire is connected to 
one side contact bus while the second comb fingers are grounded. A pulse voltage 
is applied to the cells contacting adjacent fingers. In the second mode (contact to 
common ground), an electrical pulse is applied to only one set of fingers while the 
electrically isolated, copper ground plate is placed under the device. The second 
Fig 33 Left: Direct contact to contact electrical stimulation setup. Right: Contact to common 
ground electrical stimulation setup. 
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set of fingers is used for detecting pulse propagation of the signal that has been 
passed by the cells across the non-conducting PDMS section in between. 
5.12 Conduction Velocity Measurement 
The circuit depicted in Figure 34 is used for conduction velocity 
measurement. The contact to common ground electrical stimulation setup is used. 
Cells grown on the device and signals are detected and visualized on an 
oscilloscope; the pulse propagation time is measured on the oscilloscope. After 
the measurement, devices are removed and stained. The length of the PDMS only 
gap between the gold conductive sections is measured for the conduction velocity 
calculation: Conduction Velocity= PDMS Band Length
Δt
. 
 
Fig 34 Sample oscilloscope interface for conduction velocity readout. Yellow trace is the input 
signal of a 4V, 2ms pulse. The blue trace is the detected signal on the other side of the non-
conducting band. The time measured between the stimulus pulse in blue and the next spike in the 
trace is used to calculate the conduction velocity across the non-conducting segment. 
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5.13 Wall Displacement Measurement and Optical Flow Detection 
Mechanical motion is imaged using an Olympus 1X81 microscope with an 
environmental chamber set to 37°C, 5% CO2 to keep the cells alive during long 
term time lapse imaging. A 20X, long working distance objective is used to focus 
on the underside of the 
wall top surface. The non-
transparent gold coating 
is leveraged for imaging. 
By viewing from the 
underside of the device, 
the wall motion can be Fig 36 Mechanical and electrical inputs required for  simultaneous stimulation. 
Fig 35 (A) Microscope setup for mechanical motion tracking. (B) Focusing on 
gold underside of 50µm wide walls. (C) Focusing on gold underside of 20µm 
wide walls. (D) Focusing on gold underside of grooved 20µm walls as 
compared to same device non-coated PDMS section with cells on. 
  
78 
more easily tracked as the gold coated wall tops show up as parallel black bars in 
the image (effectively blocking the cell bodies from appearing and making wall 
tracking more achievable) as seen in Figure 35. With the correct contrast and using 
a custom computer vision code built in openCV and Python to detect motion using 
dense optical flow methodology, the wall displacements can be tracked and 
correlated to applied forces. 
In brief, a video of the platform recorded by the microscope camera 
(Hamamatsu ORCA-Flash 4.0) is input to the image processing code, and the 
following procedure is iterated on every frame.  First, an edge preserving blur 
technique called anisotropic diffusion is applied to reduce image noise while 
maintaining clarity in image features.  Then, the frame is compared to the first 
frame in the sequence using a dense optical flow algorithm developed by Gunner 
Farnebäck and implemented in OpenCV112,113.  Dense optical flow methods 
calculate apparent movement between frames for every pixel location.  The 
advantage over a sparse method is it does not limit tracking to only areas of stable 
feature points and instead allows one to observe movement everywhere in the 
frame.  The dense optical flow output is sampled over a grid of points, and pixel 
movement is converted to physical movement in microns, which allows calculation 
of the force based on the prescribed model of the walls, assuming the number of 
cells, entire area of motion, and direction of alignment is known. Assumptions for 
this proof of concept study are explained further in the validation section. For 
visualization of the calculated forces, colored arrows corresponding to a force 
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scale are drawn on an output video to indicate the magnitude of the forces 
detected.  Arrows below noise thresholds are suppressed in the visualization to 
enhance focus on bending movement in the 1-2 micron range, which is the result 
of cells actually contracting - not just an artifact of noise in the image. 
 
5.14 Synchronization of Electrical and Mechanical Stimulation 
A setup has been designed to coordinate electrical stimulation according to 
EKG signaling with linear motion approximated by left ventricular volume change 
during a beat cycle. As seen in stimulation profiles derived from typical patient data 
in Figure 36, the blue curve is the ventricular volume as a function of time, which 
by approximating the chamber as a sphere allows for calculating the change in 
circumference and the relative change in length of the device (shown in green). 
The yellow trace is displacement over time and can be correlated to the voltage 
needed to drive the motor during each time step. The red is the overlaid EKG signal 
that is used to drive the electrical stimulation in coordination with the mechanical 
Fig 37 Circuit for synchronized electrical and mechanical stimulation. 
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movement. The coordination 
of the mechanical and 
electrical stimulation is made 
possible by using a one-
direction translation stage 
driven by a circulating disk with 
an axis of rotation offset by half 
the distance of the intended 
maximum displacement of the 
device while the disk is 
mounted on a DC motor shaft 
as shown in Figure 38. This 
disk is flush with a spring 
loaded stage holding one edge of the device; the other edge is fixed to a stationary 
platform at a height equal to that of the spring loaded stage. Thus, as the motor 
rotates, it stretches and relaxes the device. A simple mechanical design is used to 
generate electrical pulses. A spring wire attached to the circulating disk is able to 
contact a circuit trigger that signals the pulse generator to send an electrical 
stimulus to the device. By choosing the relative position of the wire which triggers 
the signal or by applying a delay circuit, different phase shifts (lead/lag) in 
mechanical and electrical stimulation can be realized. The circuit for synchronized 
electromechanical motion is depicted in Figure 37. 
Fig 38 Actual experimental setup for synchronized 
electrical and mechanical stimulation. 
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5.2 Validation Experiments 
5.21 Cellular Survival and Alignment on Device 
Cells seeded on devices survived stimulation for up to 24 hours at 4 V, 1 
Hz, 2 ms wide pulses. Cells were well aligned after stimulation on “5010” good 
devices (5010 denotes a specific geometry starred in the fabrication section) as 
seen in Figure 39. On bad devices, narrower wall widths caused the cells to align 
with the walls and not perpendicular to them. Larger gaps allowed the cells to crawl 
down in between walls, preventing cells from touching two contact fingers and from 
forming sheets on top of the device. Larger groove ridge patterns were too wide 
and the cells failed to consistently recognize the architecture. Both good and bad 
alignment seemed to be enhanced by electrical stimulation.  
Bovine vascular smooth muscle cells (BVSMCs) were seeded on devices 
of different geometry combinations (wall, groove width/height dimensions) at 
300,000 cells each; devices were 
both stimulated for 3 hours with 2 
ms wide pulses at 4V and a 
frequency of 1 Hz and 
unstimulated after initial cell 
attachment. A ThermoFisher 
Scientific live/dead, 
viability/cytotoxicity stain was 
used to evaluate cell survival and 
Fig 39 Alive and properly aligned BVSMCs on the 
device; walls are parallel to the top edge of the page 
and grooves are perpendicular.  
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visualize alignment using FITC/TRITC/Brightfield illumination on an Axiovert S100 
Microscope at 5X magnification, confirming that “5010” geometry and stimulation 
resulted in cellular alignment. 
5.22 Electrical Stimulation and Conduction Velocity Measurement 
BVSMCs were seeded on “5010” devices at 25,000-800,000 cells per 
device and allowed to attach overnight. Nuclei staining after testing was used to 
confirm that attached cells correlated with original seeding densities. Live/dead 
staining was again used to confirm cell survival and also, to confirm that a cellular 
connection was bridging the gap between gold electrodes; this is necessary for the 
signal to pass from the stimulation input to the readout electrode. The circuit 
depicted in Figure 35 was used for stimulation and detection of signal that had 
been transferred by the cells across the non-conducting section of the device. 
Devices were stimulated with 2 ms wide pulses at 4V and a frequency of 1 Hz. To 
Fig 40 Conduction velocity values measured on device.  
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make sure the method was detecting conduction velocities with physiological 
relevance, iPS-cardiomyocytes were also tested at low seeding densities due to 
limited availability of this cell type. Ethanol was added to some devices with 
BVSMCs during stimulation to see if the signal could be eliminated as the cells 
died. 
Figure 40 shows conduction velocity measurements for BVSMCs as a 
function of cell seeding density. Measured conduction velocities seemed to be 
physiologically relevant as smooth muscle cell velocities are documented in the 
literature from as low as 2 mm/s up to 40 mm/s114. Conduction velocity seemed to 
be independent of seeding density, but this is not unexpected if there are enough 
cells to bridge the gap between electrodes, which was shown with cellular staining. 
While there were a limited number of data points for the iPS-cardiomyocytes, they 
had higher conduction velocities than BVSMCs, which is also to be expected. 
5.23 Detection of Mechanical Motion  
Four hundred thousand BVSMCs were seeded on “5010” devices. They 
were transferred to the Olympus 1X81 microscope environmental chamber and 
imaged with the 20X, long working distance objective as the cells attached to the 
device. No motion was detected using the dense optical flow program; this was 
believed to be because of the short, wide wall geometry, which is too stiff to be 
sensitive enough to these cellular traction forces. This presented a tradeoff: cells 
would not grow on top of very skinny walls, but forces could not be detected on 
very wide walls.  
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To overcome this problem, a new 
device with 17 µm wide, 76 µm tall walls 
and a 23 µm gap between walls was 
fabricated (no groove/ridge pattern). 
These gaps were then filled in with the 
relatively, very soft Matrigel (modulus of 
500 Pa as compared to 750 kPa for 
PDMS).  
Cold Matrigel at full concentration 
was pipetted onto devices chilled on ice 
and then put under vacuum for 1 hour to 
allow the gaps in between walls to be filled 
in. After 1 hour, a thin plastic membrane 
was placed on top of the device and then 
slid off to remove excess Matrigel. 
Devices with Matrigel were placed in the incubator for 15 minutes prior to cell 
seeding. As seen in Figure 41, BVSMCs attached to the top of the device, spanning 
walls and gaps. The effect of the soft gel in between the PDMS walls on 
mechanical motion and bending was evaluated using Comsol as shown in Figure 
42, showing minor reductions in displacement. When iPS-cardiomyocytes were 
seeded on the device, they attached as well as shown in Figure 43. While some 
Fig 41 (Top) Brightfield image looking down 
on top of device, showing walls and gaps. 
(Bottom) FITC image of cells crossing walls 
and gaps at same focal plane, demonstrating 
Matrigel has filled in gaps. 
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wall motion was evident, most cells aligned with the Matrigel and contracted 
parallel to the walls, preventing consistent image tracking of displacement.  
 To overcome this problem, a device with 23 µm wide, 89 µm tall walls with 
groove/ridge patterning was fabricated; gaps were then filled in with relatively, very 
soft Matrigel (modulus of 450 Pa as determined by atomic force microscopy115 and 
as compared to 750 kPa for PDMS). iPS-derived cardiomyocytes (BJ RiPS-D - 
Healthy Donor Control (Male), 
generated by HSCI iPS Core at 
Harvard University) were seeded on 
the device, attached, spread across 
the top, and were imaged contracting 
such that wall displacements could be 
detected with the image tracking 
program. The black stripes seen in 
Figure 44 (A) are the undersides of 
Figure 42 Demonstration in the change of wall displacement between a free standing wall and 
one where a very soft gel has been filled in between the walls.  
Fig 43 iPS-cardiomyocytes seeded on top of 
Matrigel-filled in device. At edge of device, cluster 
of cells can be seen attached to wall. When they 
beat, this wall is visibly displaced. 
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tops of walls coated with gold, and the code was customized to track maximum net 
displacement of these stripes and calculate a total force applied to cause this 
maximum net displacement. This total force was divided over the estimated 
number of cells in the viewed area to get an approximate force per cell. Total force 
profiles over time for 5 different cell clusters are shown in Figure 44 (B). Based on 
this and approximated cell numbers/area, beat forces per cell (~100-300 nN/cell, 
depending on the assumed number of stacked cells) are on the same order of 
magnitude as those measured by the cell provider and the literature.  
In order to make this initial approximation of force per cell, several 
assumptions were made for this setup. The area analyzed was set to capture 
clusters of isolated motion and all cells in the field of view were assumed to apply 
force collectively in a direction perpendicular to the wall. The lack of motion in the 
surrounding areas was assumed to be due to either no cells or non-beating cells 
being present in these areas and not because beating forces were being equally 
applied in opposite directions. As cells connect to form a sheet or tissue, it has 
been shown that the contractile forces may only be read out at the edges of the 
continuous sheet as those cell forces in the middle of the sheet cancel each other 
out116. However, in this experiment images were taken 3 days after seeding when 
a continuous sheet had yet to form. 
The device is designed to be able to monitor and measure net force applied 
by clusters of cells as they are seeded initially and as they connect to form a sheet. 
This, therefore, requires more complex analysis going forward. First, the profile of 
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all walls across the entire device 
area needs to be determined by 
scanning and stitching images 
together. Then, the entire area 
can be evaluated to identify 
regions that are beating 
collectively together; these areas 
should have similar opposing wall 
motion at either end of the cluster. 
Each section can then be 
evaluated for a maximum force 
per area. Individual wall bending 
profiles within the cluster can be 
used to visually evaluate 
uniformity throughout this cluster, 
and eventually the sheet.  
5.24 Simultaneous Linear Actuation and Electrical Stimulation 
Initial testing of devices stretched over a total distance of 1 mm and 
simultaneously stimulated with 2ms pulses at 4V at a frequency of 1 Hz were 
performed to test if cells survived this conditioning for 3 hours. While there were 
more dead cells than electrical stimulation only tests, the majority of cells were still 
alive and aligned as evident in Figure 44 below.   
Fig. 44 (A) Screenshot of video of iPS-derived 
cardiomyocytes beating on the device. Black stripes 
are the underside of the top of walls coated with gold. 
(Left) Wall motion caused by cells without tracking in 
161µm x161µm area. (Right) Same area with tracking. 
(B) Max force seen on device over time. Profiles shown 
for 5 different areas (cell clusters) on the device. When 
a cell diameter of 30 µm is assumed, it is estimated 
that there are 37 cells covering a monolayer for this 
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5.25 Triggered Cell Sheet Release  
Devices were coated with a 
custom synthetic oligopeptide, 
CCRRGDWLC, according to a 
published protocol117 and then 
seeded with BVSMCs at various 
seeding densities. The cells were 
allowed to grow to confluent sheets 
and then -1V was applied across the 
device for 5 minutes using a DC 
power supply where the positive 
lead was attached to the wires 
extending from the electrical contact 
pads and the ground lead was 
attached to a platinum wire 
suspended in PBS within the well. 
According to the paper, this breaks 
the thiol bonds and allows for 
release of the cell sheet. While cells 
were overgrown on devices and 
lifted off as partial sheets on their own, the gold-peptide protocol for cell sheet 
release has yet to be realized. A Matrigel lift-off technique also resulted in some 
Fig 45 Simultaneous mechanical and electrical 
stimulation. (A) Output from oscilloscope in yellow 
shows linear displacement of device and in blue 
shows pulse profile overlap with stretching. Sample 
patient data is plotted below for EKG in red and 
scaled device displacement in green. (B) Live 
(green) / dead (red) staining of device after 3 hours 
of stimulation. 
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fractional sheets, but a full release protocol still needs to be optimized. It is 
promising that the geometry supports confluent cell growth.  
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CHAPTER SIX: CONCLUSIONS AND FUTURE WORK  
 
6.1 Conclusions  
pMSCs were characterized as a cell source for myocardial cell sheet 
fabrication and implantation. Based on the results presented, pMSCs offer a 
cardiac benefit in their undifferentiated form through paracrine effects on migration 
and proliferation, show potential for cardiac compatibility, are readily available, and 
are compatible with scaffold-less cell sheet technology. This pMSC work was the 
motivation to design a device that would allow for the functional characterization 
and conditioning of cell sheets made from non-cardiomyocyte cell sources. 
A device was created that allows for patient based electrical and mechanical 
stimulation of cells and cell sheets. It allows for readouts on cellular contractility 
and conduction velocity in the culture. At the end of characterization and or 
conditioning, the cell sheet can be released for implantation. In order to evaluate if 
the initial design criteria were met, the original objectives are presented in Table 
8. As documented above, experimental evidence for 5 of the 6 criteria were 
achieved. For cell sheet release, only partial sheet release has been achieved at 
this time as indicated by the yellow check mark. 
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Table 8 Design criteria checklist. 
Design Criteria Realization in the Device Validation Testing ? 
Cell survival and 
alignment on the 
device 
Surface conducive to cell 
attachment and spreading; 
patterning that causes cells 
to align 
Confluent, healthy cell sheet 
grown on device 
 
Readout of cell 
sheet contractility 
Bending element is 
displaced enough under 
cellular force such that it 
can be detected in the 
microscope 
Detection of wall motion due 
to cell contractility using 
microscope and subsequent 
image tracking  
Readout of 
conduction 
velocity 
Signal input into one 
electrode can be detected 
at another electrode 
Measured physiologically 
relevant conduction velocity 
across device  
Electrical 
stimulation 
Electrodes patterned on 
device 
Stimulation over time 
without killing cells 
 
Mechanical 
stretching 
Pliable substrate that can 
be pulled 
Stretching synchronized 
with electrical stimulation, 
cell survival over time  
Ability to implant 
cell sheet that has 
been 
characterized 
Apply oligopeptide 
technology to gold 
Apply hydrogel release 
system in between walls 
Release cell sheet from 
device alive and 
undamaged  
 
In general, device fabrication and validation are promising steps forward in 
the direction of patient customized myocardial therapy and standardization of 
tissue engineering solutions. However, several aspects of device design require 
optimization going forward.  These are discussed in the sections following. 
6.2 Combining All Modalities 
In the validation presented here, design aspects were tested individually. 
While there was demonstration of simultaneous electrical and mechanical 
stimulation, measurements of contractility and conduction velocity were done 
independent of each other. Ultimately, a computer program and device platform 
should be created such that all parameters can be run and monitored 
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simultaneously through the program 
interface. In addition, the platform 
should have the capability to run 
multiple devices at one time such that 
designs of experiments can easily be 
used to optimize patch performance. 
In order to make output data easier to 
work with, determining a way to read 
out the mechanical contractility 
electronically would be very beneficial. 
Employing piezoelectric or electroactive polymers in the device or creating a 
capacitance measurement using the gold tops of the walls are potential options 
worth exploring. In addition, finding ways to link in patient data in addition to EKG 
and ECHOs would add additional inputs for patient customization; one example is 
using implant site geometry and tissue stiffness as derived from MRIs of the 
patient’s heart to inform the geometry of the device area. 
 
6.3 Validate with iPS Cardiomyocytes then use with pMSCs  
Once the combined platform has been created, the device should be used 
to test iPS-derived-cardiomyocytes’ responses to patient-specific 
electromechanical stimulation. In this experiment, iPS-cardiomyocyte cell sheets 
would be exposed to stimuli associated with different patient data over a range of 
defects and ages. The goal would be to see how different stimulus inputs affect 
Fig 46 Sample Design of Experiments for 
conduction velocity and contractility as functions 
of patch geometry, electrical stimulation, and 
mechanical stretching.  
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the following outputs: conduction velocity, contractility, calcium reporter signaling, 
and cellular phenotype over time. Electrical and mechanical stimulation profiles 
can be derived from a de-identified patient data bank of EKG and echocardiogram 
files for different ages and heart conditions. Additional profiles (not naturally seen 
in the heart) can also be created and used for stimulation; data collected from 
these stimulation experiments may give insight into how cells can be conditioned 
in future experiments.  
Once a baseline is established with iPS-cardiomyocytes, the protocols 
would be applied to pMSCs. Three related experiments could be carried out: (1) 
pMSCs would first be stimulated with the same profiles as described for iPS-
cardiomyocytes to determine how their responses differ from cardiomyocytes; (2) 
pMSCs would be stimulated for 7 days with a healthy heart profile and then 
exposed to control stimuli not associated with a healthy heart; the respective 
responses would be compared. (3) Finally, a base layer of iPS-cardiomyocytes 
would be established on the device. A second layer of pMSCs would be added on 
top of the iPS layer. The same stimuli profiles applied to iPS-cardiomyocytes and 
pMSCs alone would be applied to the bi-layer, mimicking the contact of a single 
cell layer pMSC patch with a single cell layer myocardial wall. This valuable set of 
experiments would finally bring the story full circle; using the designed device to 
evaluate the cell source that was the original motivation for the work.   
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CHAPTER SEVEN: SUPPLEMENTARY VENOUS VALVE WORK FOR 
CARDIAC IMPLANTATION118 
 
Despite improvements in valve repair techniques and outcomes, children 
with irreparable valves require valve replacement.  A primary unmet need crucial 
to pediatric valve replacement is the availability of small pediatric valves, and the 
ability of the replacement valve to adapt to the growing child.  The options for 
pediatric valve replacement include mechanical, allograft and xenograft valves.  
There are limited valve replacement options for diameters less than 15 mm, and 
all prosthetic valves suffer from fixed diameter119. Attempts to enlarge bioprosthetic 
valves, particularly right ventricular outflow tract (RV-PA) conduits, often result in 
regurgitation.  Recent experience with an externally stented bovine jugular vein 
graft as an expandable valve for prosthetic replacement in mitral position has 
prompted investigation into potential design for pediatric expandable valves that 
might limit the frequency of reoperation for valve replacement120. 
A potential source of small-sized valves for an expandable design is cryo-
preserved allograft femoral or saphenous vein.  Similar to other venous valves, 
they are capable of retaining competence over a wide range of sizes, which makes 
them ideal for use in an expandable valve design.  The thin support structure 
surrounding the valve and high internal to external diameter (ID/OD) ratio makes 
them favorable for intra-cardiac implantation within small annuli. Experience with 
the unsupported configuration of this valve in the RV-PA position has 
demonstrated favorable short term competence121. We describe and test a 
prototype design utilizing allograft venous valve within a stent. 
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7.1 Expandable Stent Venous Valve Sutured Constructs for Surgical 
Implantation 
7.11 Materials and Methods 
Expandable valve design and in vitro testing:  
A 14 mm native diameter cryo-preserved femoral vein graft (Cryolife Inc, 
Kensaw, GA) was thawed in a warm water bath. A segment of vein containing the 
valve was excised from the original graft and compressed within a 22 mm CP stent 
(NuMed, Hopkinton, NY) that was pre-expanded to 10 mm diameter.  The proximal 
and distal ends of the vein conduit were trimmed and sutured to the edges of the 
stent.  
The femoral venous valve construct was subjected to in vitro testing to 
determine valvular competence over a range of diameters.  Competence was 
A) 
Fig 47 Competence testing of the valve (A,B) without and (C) with applied pressure. (D) Method 
of expansion to get stent valve construct to 12 and 14 mm diameters. 
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determined by passive instillation of fluid into the valve sinuses either under 
pressure, or merely gravity (Figure 47).  Testing of valvular competence was 
performed at compressed configuration (10 mm OD) and following expansion to 
10 mm, 12 mm, 14 mm, and 16 mm ID. 
Morphological Measurements:  
Femoral venous valves (n=4) of various ID were longitudinally incised in 
order to measure valve dimensions under non-distended conditions.  The ratio of 
commissural height (linear distance from top of commissural post to base of leaflet) 
to valve ID was calculated for each valve, and the median (range) is reported.   
Pilot Clinical Testing:  
Valved venous construct was utilized for implantation in the RV-PA position 
in 2 patients.  Patient characteristics and implantation techniques are reported.  In 
both patients, thawed saphenous or femoral vein graft was insufflated in order to 
identify the segment containing the valve.  The valve segment was secured within 
an 8 mm Palmaz Biliary Stent (Cordis, Bridgewater Township, NJ) that was pre-
expanded to desired ID.  Following implantation, valvular function was assessed 
by echocardiogram.  Impact of catheter-based valve enlargement on performance 
was also assessed by echocardiogram. 
7.12 Results 
In Vitro Testing and Valve Measurements: 
 Valvular competence was assessed under compressed configuration (10 
mm OD) and following expansion to 10 mm, 12 mm, 14 mm, and 16 mm ID.   At 
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10 mm configuration, the valve was functional under low and high pressure 
conditions.  Valve competence under low pressure conditions was observed 
following balloon expansion to 12 and 14 mm ID.  At 16 mm ID, the vein wall 
detached from the stent frame and the valve was incompetent.  Measurements of 
valve leaflet dimensions under non-distended conditions revealed a median height 
of 0.6 (range 0.4 to 0.7), ID of 0.5 (range 0.4 to 0.5), and height to diameter ratio 
of 1.1 (range 0.9 to 1.7). 
Patient 1:  
A 4 day old child with hypoplastic left heart syndrome and borderline 
hypoplasia of the left ventricle underwent stage 1 palliation with aortopulmonary 
amalgamation, aortic arch reconstruction, and restriction of the interatrial septum.  
In order to promote antegrade pulmonary blood flow, valved RV-PA reconstruction 
was performed.  Expandable valve design was chosen to provide the option to 
delay the subsequent biventricular repair surgery. 
 Thawed saphenous vein graft was insufflated in order to identify the 
segment containing an 8 mm OD valve and this segment was excised.  The valve 
Fig 48 (Left) Saphenous vein-stent construct is (Right) implanted in patient 1. 
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segment was compressed and sutured within an 8 mm Palmaz Biliary Stent 
(Cordis, Bridgewater Township, NJ) which was pre-expanded to 6 mm.  The 
proximal portion of the RV-PA graft was constructed with externally reinforced 5 
mm PTFE graft (Gore Corporation) that was inserted transmurally into the RV 
through a small ventriculotomy122.  The distal anastomosis to the pulmonary artery 
bifurcation was performed with a bovine pericardial patch into which a 5 mm PTFE 
graft was inserted.  The saphenous vein construct was interposed within the two 
segments of PTFE, and the anastomoses of conduit wall to PTFE were performed 
with 6-0 Prolene suture (Figure 48). 
Echocardiography was used to determine competence of the valve 
intraoperatively, and at 2 weeks and 1 month postoperatively.  At 4 months 
postoperatively, the valve construct was balloon dilated to 8 mm ID in the 
catherization laboratory, resulting in trivial to mild regurgitation. 
Patient 2:  
A 4-month-old female with history of double outlet right ventricle, 
transposition of the great arteries, pulmonary atresia, total anomalous pulmonary 
venous connection, and discontinuous pulmonary arteries underwent stage 1 
palliation in the newborn period.  At 4 months of age, she developed hypoxia, but 
was not felt to be a candidate for cavopulmonary shunting due to pulmonary artery 
and venous obstructions.  RV-PA conduit with an expandable valved conduit was 
preferred to promote antegrade pulmonary blood flow and delay timing of 
biventricular conversion. 
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A 10 mm (OD) femoral vein valve segment was compressed and sutured 
within an 8 mm Palmaz biliary stent which was pre-expanded to 8 mm. The 
proximal portion of the RV-PA graft was constructed with transmural insertion of 
externally reinforced 6 mm PTFE.  The anastomoses between the distal segment 
of the vein construct and the right pulmonary artery and the proximal segment to 
the PTFE graft were performed with 6-0 Prolene suture. 
Echocardiography was used to determine competence of the valve 
intraoperatively, and at 2 weeks and 1 month postoperatively.  Trivial to mild 
regurgitation was observed at each time point.  Catheterization will be performed 
for balloon dilation of the valve if the patient becomes cyanotic. 
7.13 Discussion 
This study describes a prototype of an expandable valve for pediatric 
application that consists of a cryo-preserved human venous graft constrained 
within a stent frame.  The construct demonstrates valvular competence in vitro at 
a range of diameters, and satisfactory short-term performance in RV-PA position 
in pilot clinical testing. Valvular competence following expansion was 
demonstrated in one patient 4 months following initial implantation. The design 
was chosen based upon previous experience with bovine jugular vein graft within 
stent construct (Melody® valve) and clinical experience with cryo-preserved human 
saphenous and femoral vein graft121. 
Certain design features of the reinforced venous valve make it ideal for 
expandable valve prosthesis.  A venous valve is capable of adapting to changes 
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in cross sectional diameter which result from physiological variations in venous 
pressures.  The ratio of commissural post height to cross-sectional diameter 
demonstrated in this study (1.1) is significantly larger than values reported for 
semilunar valves (0.5 – 0.7)123-125. The elongated commissural height may 
preserve leaflet coaptation and valvular competence over a physiologic range of 
diameters. The thin support tissue surrounding the venous valve allows favorable 
ID/OD ratio and effective orifice area, even when the construct is compressed to 
diameters significantly less than the native diameter of the valve.  This construct 
enables a strategy of implantation at compressed configuration followed by 
subsequent catheter-based expansion to diameters within the physiologic range 
of that valve. Furthermore, a venous valve is well suited for pediatric cardiac valve 
replacement as the leaflet tissue consistency matches that of a neonate or infant.  
Thin, pliable leaflets permit valve opening and closing with lower forces, which 
translates into less gradient across the valve. In contrast, the relative rigidity of 
pericardial or mechanical prosthetic leaflets contributes to a gradient across these 
valves, especially when implanted into the mitral or tricuspid positions126. 
External support with a stent is a crucial design feature of this expandable 
valve construct.  Venous valves function at a range of physiologic diameters, but 
exhibit incompetence once expanded beyond a threshold ID.  The stent maintains 
the valve in a compressed state and allows regulation to diameters less than the 
maximum threshold.  At subsequent dilation, the valve can only be expanded up 
to the native diameter of the original vein graft, as regurgitation is expected beyond 
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this diameter.  Under externally supported conditions, the venous valve is capable 
of withstanding systemic arterial pressures, as long as the diameter does not 
exceed native diameter127. 
Additional advantages of a venous valve are that it is less rigid than 
semilunar prostheses and less amenable to calcification. The use of allograft rather 
than xenograft tissue also minimizes chances of xenograft response and may 
improve the likelihood of native cell infiltration and growth.  In contrast to 
mechanical prostheses, this prosthesis would not require systemic 
anticoagulation; anti-platelet therapy with aspirin is likely sufficient.  In contrast to 
the 22 mm bovine jugular vein valved graft, allograft venous valves are available 
in sizes less than 15 mm, which are applicable to neonatal valve replacement. 
Design modifications are required to optimize stent length, attachments of 
the vein graft to the stent, and implantation of the construct into the annulus. 
Additional considerations for intra-annular implantation include selection of a stent 
that would be rigid enough to withstand physiologic annular compression, yet 
amenable to transcatheter balloon dilation.  Fatigue testing under dynamic 
pulsatile flow conditions is needed to evaluate the performance over multiple 
cycles. 
The design described in this study seeks to create a pediatric biological 
valve that can be implanted at diameters less than 15 mm, yet expanded by 
transcatheter dilation as a child grows.  It utilizes a currently commercially available 
cryo-preserved venous allograft compressed within a stent housing.  The valve 
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functions acutely at several diameters, and has 
demonstrated acute functionality in several patients.  
Design features must be customized according to the 
intended position of implantation and further 
standardization is necessary prior to expanded clinical 
application. 
7.2 Exploration of Venous Valve Properties  
While the technology has already been surgically 
implemented, the long-term durability, patency, and 
performance of the implanted valves have yet to be 
evaluated. One method for evaluating the performance 
of this construct is through mechanical finite element 
modeling of the system, where the applied forces are 
those induced by blood flow in the beating heart. 
However, in order to do this, it is necessary to understand the geometry and 
material properties of human femoral vein valves. There is little published data on 
the shapes/geometry of normal venous valve leaflets and their mechanical 
properties. In this study, we characterize both for CryoLife cryo-preserved adult 
femoral veins, which are currently being surgically implanted. Leaflet and 
commissure geometry is analyzed and full leaflets are excised for biaxial testing to 
establish material curves for finite element analysis. This characterization paves 
the way for quantitative understanding of venous valve function and application of 
Fig 49 Implanted 
construct, consisting of 
femoral vein valve 
sutured into expandable 
titanium stent. After 
surgical implantation, the 
valve diameter can be 
expanded using a balloon 
catheter to accommodate 
child growth. 
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its principles to pediatric heart valve 
surgical repair.  
Modeling venous systems under 
cardiac conditions is vital because in vivo 
vein valve function differs from heart valve 
function due to the different hemodynamic 
environments. Heart valves operate in 
higher pressure, higher flow environments and their valve closure is driven by flow 
as opposed to vein valves where closure is driven by a drop in sinus pressure. 
While the geometry and elasticity of vein valves may be comparable to or even 
better than existing heart valves, it is important to confirm that the vein valves are 
able to withstand the pressure and flow conditions presented by the cardiac 
environment. 
7.21 Materials and Methods 
Femoral Vein Leaflet Dissection:  
Veins were insufflated using a syringe as to better visualize valve location 
and commissure attachment so valves were not damaged during the excising 
process. Once valve location was marked, the vein was cut into 1-2 cm sections 
that each captured a section containing a valve. These sections were then inverted 
without damage to the leaflets and the leaflets carefully cut away from the vein wall 
using surgical scissors and forceps. Photographs and measurements that 
captured valve and leaflet geometry including valve diameter, commissure height, 
Fig 50 Biaxial Test Setup. 
CellRake 
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leaflet width and height, and overall leaflet count were taken. Dissected leaflets 
were then stored in PBS until they were mounted for biaxial mechanical testing. 
Biaxial Mechanical Testing:  
All biaxial testing was performed using the CellScale BioTester setup (4.5 
mm wide CellRake attachments and 2.5 N load cells). The entire leaflet was 
mounted, aligning the x-axis with the circumferential direction of the leaflet and the 
y-axis with the radial direction of the leaflet as seen in Figure 50. All tests were 
performed with the leaflet submerged in a 37˚C PBS1X bath. Thickness 
measurements were taken at the time of testing using calipers; an average 
thickness value was assumed for all leaflets during data processing. The initial 
protocol, tested on 9 leaflets, was based on the Billiar Sacks protocol for aortic 
cusps128. To ensure that testing captured a physiologically relevant stress zone, 
we used a range of relevant pediatric valve diameters and pressures seen in the 
heart to approximate the stresses seen in the leaflet.  To calculate stresses based 
on these values, we assumed the shape of the leaflet can be approximated by a 
thin hemispherical shell where the stress is a function of the valve diameter, 
pressure and assumed constant thickness of 0.5 mm (this in reality is variable) as 
shown in the equation below.  Looking at the range of stress values in Table 9, we 
chose to target 100 kPa with our load protocol and scaled the Sacks Billiar protocol 
accordingly.  
σLc=
pd
4tc
, tc=0.5 mm 
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Table 9 Expected stresses experienced by leaflet tissue for different diameter valves and 
pressures. 
 
Diameter 
(mm) 80 100 120 
Pressure 
(mmHg) 
5 27 33 40 kPa 
10 53 67 80 kPa 
15 80 100 120 kPa 
20 107 133 160 kPa 
 
The protocol for the first set of tests can be seen in Table 10. A preload force of 10 
mN was applied in both directions. Seven different force ratios were evaluated over 
20 second stretches and relaxations. Four cycles were performed at each force 
ratio step and the first 30 data points from the fourth stretch were used for data 
processing. 
Table 10 List of circumferential and radial forces applied during the protocol. 
 
Run 
Circumferential 
Force Applied 
(mN) 
Radial Force 
Applied (mN) 
1 100 25 
2 100 50 
3 100 75 
4 100 100 
5 75 100 
6 50 100 
7 25 100 
 
Upon completion of this testing and preliminary data analysis, it was determined 
that a more physiologically relevant stretch and relaxation time frame should be 
considered in order to confirm that the mechanical properties were independent of 
the stretch time scale. The time was reduced from 20 to 1 second as to better 
mimic the movement seen during a heartbeat. Five leaflets were tested using 5 of 
the force ratios from the original protocol (highlighted in Table 10). Twelve cycles 
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were performed at each step and all data points from the twelfth stretch were used 
for data processing.  
Data Analysis and Model Fitting:  
Two model equations for strain energy were used to fit the biaxial 
mechanical data129-133: 
 
Fung: W= C2 (eA1E112 +A2E222 +2A3E11E22+A4E122 -1)  
Chew: W= B2 �Ex2+Ey2�+BxyExEy+ C2 �eAxEx2+AyEy2-1�Error!  Bookmark not defined. 128 
  
Data collected from the biaxial testing included forces (f) applied in the x and y 
directions and relative displacements of the CellRakes from their initial positions. 
From this information, the experimental first (P) and second (S) Piola-Kirchhoff 
(PK) stress tensors were calculated as follows134: 
Pexp=
f
Axs,orig
  
Sexp=inv(F)*P where F(λ)=deformation matrix  
Sexp=
Pexp
λ
  
 
The second PK stress tensors were also calculated from the model equation and 
the Green Strain values (E) as follows: 
Smod=
∂W
∂E  where  
E=
1
2 *�F
'*F-I�=
1
2 (λ
2-1) 
 
By using the lsqnonlin function with the Levenberg Marquardt solving option in 
MATLAB, code was written to minimize the difference between the experimental 
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and model second PK stress values by varying the respective parameter values in 
the model strain energy equations. 
7.22 Results 
Femoral Vein Leaflet Dissection and Measurement:  
Eight leaflets were used to measure the dimensions listed in Table 11. Most 
valves consisted of two leaflets, but some tri-leaflet valves were present. Leaflet 
dimensions were variable and valve dependent.  
Table 11 Geometry of venous valve leaflets. 
 Height 
(mm) 
Width 
(mm) 
Area 
(mm2) 
Perimeter 
(mm) 
Commissure 
Length (mm) 
Free 
Edge 
(mm) 
Height to 
Width 
Ratio 
Commissure 
to Free Edge 
Ratio 
Average 
(n=8) 7.4 13.6 67.2 39.1 23.4 15.6 0.6 1.6 
Std. Dev. 1.5 2.8 10.8 4.6 3.6 3.3 0.2 0.5 
 
Biaxial Mechanical Testing Model Fits:  
Using the MATLAB code and logic outlined in the methods section, 
parameters for both strain energy model equations were solved for data sets from 
both the long and short stretch test protocols. Data sets for the long stretch protocol  
 
consisted of the first 30 data points of the fourth stretch for each of the seven force 
ratios. Data sets for the short stretch protocol consisted of all data points of the 
12th stretch for each of the five force ratios. Average parameter values and 
standard deviations for both models for both protocols were calculated and are 
Table 12 Model parameters for curve fits. 
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listed in table 12; outliers were not included in the average values.  
The goodness of the fit is best analyzed by looking at the average difference 
between the experimental and model second PK stress values for each data set 
evaluated. This can be calculated as follows using the resnorm output from the 
function lsqnonlin, which is the sum of the squares of the function. The average 
deviation of an experimental data point from the calculated model value for the 
Fung and Chew equations were 29 kPa and 26 kPa, respectively. 
Deviation of Experimental from Model=�
resnorm
# of data points 
The average parameter values for both models for the short stretch protocol were 
then used to generate 2nd PK Stress vs. Green Strain curves for all force ratios 
evaluated using Excel Solver. The circumferential and radial lambda values were 
iterated upon until the experimental and model 2nd PK stress values converged. 
 
Fig 51 Solid lines represent Stress-Strain relationships in the circumferential direction. Dashed 
lines represent Stress-Strain relationships in the radial direction. 
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Fig 52 Solid lines represent Stress-Strain relationships in the circumferential direction. Dashed 
lines represent Stress-Strain relationships in the radial direction. 
 
7.23 Discussion 
In this tissue characterization, the primary concern was to determine the 
geometry and biaxial mechanical properties of femoral venous valve leaflets so 
that these parameters are more accurately represented within finite element 
models of this biological construct aimed at predicting stress-strain responses. To 
this end, two different strain energy equations were fit to this data set in order to 
analyze which one best captured the curve shapes at both very low and high strain 
values. With anisotropic, nonlinearly elastic materials, highly dependent on the 
direction of collagen and elastin fiber alignment, it is often difficult to capture all 
sections of the stress-strain relationship accurately.  
The Fung model utilizes exponential terms to capture the behavior of the 
high strain regions; this was a good start to fitting parts of the data sets. In the 
Chew model, additional polynomial terms provided a better fit to the data in the 
very low strain range. The strength of the Chew model is that it can closely fit 
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typical biaxial data where 
there is a "low stiffness" 
part of the curve (low 
stress up to a pretty large 
value of strain) followed 
by an abrupt transition to 
a "high stiffness" part 
(stress climbs rapidly for 
very little further increase 
in strain). The polynomial 
terms in the Chew model dominate for the low stiffness region while the 
exponential term dominates for the high stiffness region. However, the 
experimental data from this testing which we feel best represents physiological 
forces did not include many points in what would be the "low stiffness" region, 
making it hard to realize the advantage of the Chew model. In fact, for many data 
sets, the Fung model actually seemed more appropriate because the Fung curves 
far to the right take on exponential forms where the Chew model appears to remain 
linear with slopes that are too small to capture the data. Since our current priority 
is to best capture the high strain region, we plan to use the Fung model fits. We 
may also perform lower strain testing to confirm that the Chew model is better for 
low-strain applications. 
Error in the current data is most likely due to the variability in the fiber 
Fig 53 Comparison of vein leaflet curves generated in this 
paper to Sacks aortic leaflet curves generated in the original 
protocol. Data shown for 1:1 force stretching ratio for both 
radial and circumferential directions. 
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structure, size, and thickness between leaflets from patient to patient, vein to vein, 
and valve to valve. As each leaflet’s mechanical properties are a function of their 
fibrous structure and orientation, a range will always exist for such measurements. 
This further emphasizes the importance of sensitivity analysis in conjunction with 
model predictions to evaluate the impact of different geometry parameters such as 
thickness on strain and stress values. Error may have also resulted from 
inconsistencies in handling and mounting leaflet tissue. As the leaflets were thin 
and pliable, mounting was not always consistent and or gentle on the delicate 
tissue. Sometimes stretch runs would have to be restarted if the leaflet was not 
properly hooked by the CellRakes initially and became detached during testing. 
Due to the above errors, these curves may be improved by additional data 
collection, but we are confident enough in the data to start using these curve fits in 
initial finite element analysis of venous valve systems exposed to cardiac 
environments.  
The data validity is 
supported by the fact that the 
curves do agree with the 
general trends expected for 
circumferential vs. radial 
responses of valve leaflets. In 
addition, when compared to 
aortic leaflets (as tested by the 
Fig 54 Finite element model of bi-leaflet valve with 
Fung model of leaflet material properties applied. 
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Sacks Billiar protocol previously referenced), the differences between the 
respective curves for aortic vs. vein leaflets are plausible. When the vein leaflet 
data collected for this paper at the 1:1 force ratio is converted to tension vs. green 
strain values by multiplying the second Piola-Kirchoff stresses by the assumed 
thickness, the plots for comparison in Figure 53 can be generated. The vein leaflets 
appear to be more extendible in both directions before hitting their high stiffness 
regions. This agrees with previous studies and experimentation as well as the 
overall functionality of veins that suggests this tissue is more pliable and elastic 
than its aortic equivalent. The model fit equations can be applied to finite element 
simulations of bi-leaflet structures under pediatric, physiologically relevant loads 
as demonstrated by Figure 54. 
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